Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Trends, Growth Report 2033

Global Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

Market Size in USD Billion

CAGR : 7.30 %

Bar chart comparing the Global Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market size in 2025 - 1.02 and 2033 - 1.71, highlighting the projected market growth.

USD 1.02 Billion USD 1.71 Billion 2025 2033

Forecast Period	2026 - 2033
Market Size (Base Year)	USD 1.02 Billion
Market Size (Forecast Year)	USD 1.71 Billion
CAGR	7.30 %
Major Markets Players	Takeda Pharmaceutical Company Limited (Japan) Fresenius Kabi AG (Germany) Baxter International Inc. (U.S.) Nestlé Health Science (Switzerland) Abbott Laboratories (U.S.)

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size

The Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market size was valued at USD 1.02 Billion in 2025 and is expected to reach USD 1.71 Billion by 2033, at a CAGR of 7.3% during the forecast period. The market is witnessing steady growth due to the increasing prevalence of short bowel syndrome associated with intestinal failure, rising awareness regarding rare gastrointestinal disorders, and continuous advancements in specialized nutritional and pharmacological therapies. Growing adoption of multidisciplinary treatment approaches, coupled with improved diagnostic capabilities and enhanced patient management strategies, is further supporting market expansion.

The increasing burden of intestinal resections resulting from conditions such as Crohn’s disease, mesenteric ischemia, trauma, congenital abnormalities, and cancer-related surgeries has significantly contributed to the demand for Type 1 SBS-IF treatments. Healthcare providers are increasingly utilizing parenteral nutrition, enteral nutrition support, and glucagon-like peptide-2 (GLP-2) analog therapies to improve intestinal adaptation, reduce complications, and enhance patient quality of life.

Key Market Trends & Analysis

North America dominated the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market with the largest revenue share of 41.37% in 2025, supported by advanced healthcare infrastructure, strong reimbursement policies, and widespread access to specialized intestinal rehabilitation centers.
The Nutritional Support Therapy segment led the market with a 41.93% share in 2025, driven by its critical role in maintaining hydration, nutrient absorption, and overall patient management during intestinal recovery.
Asia-Pacific is expected to be the fastest-growing region at a CAGR of 8.0% from 2026 to 2033, fueled by improving healthcare accessibility, increasing awareness of rare gastrointestinal disorders, and growing investments in advanced treatment options across emerging economies.
Emerging and Advanced Therapies are the fastest-growing treatment modality segment, projected to register a CAGR of 7.7%, reflecting increasing adoption of innovative biologics, GLP-2 analogs, and regenerative treatment approaches aimed at reducing long-term parenteral nutrition dependence.
The Core SBS-IF Market segment dominated the market attribution category with a 56.73% revenue share in 2025, supported by the substantial patient population requiring specialized and continuous intestinal failure management.
The Acute Phase (Type 1 SBS-IF) segment accounted for the largest share of 48.47% in 2025, driven by the immediate need for intensive nutritional support, fluid management, and clinical intervention following major intestinal resection or injury.
The Adaptation Phase segment is anticipated to be the fastest-growing phase category, registering a CAGR of 7.6% during the forecast period, owing to increasing focus on therapies that enhance intestinal adaptation, improve nutrient absorption, and support long-term patient recovery.

Market Size & Forecast

Global Market Value (2025): USD 1.12 Billion
Expected Market Value (2033): USD 1.71 Billion
Forecast CAGR (2026–2033): 7.3%
Leading Region in 2025: North America
Fastest Growing Region: Asia-Pacific

Report Scope and Type 1 SBS-IF treatment market Segmentation

Attributes	Type 1 SBS-IF treatment Key Market Insights
Segments Covered	By Treatment Modality: Nutritional Support Therapy, Pharmacological Therapy, Surgical & Interventional Treatment, and Emerging & Advanced Therapies By Market Attribution: Core SBS-IF Market, SBS-IF Attributable Market, and Adjacent / Non-Specific Market By Disease Management Phase: Acute Phase (Type 1 SBS-IF), Adaptation Phase, and Recovery Phase By Patient Type: Adult and Pediatric By Route of Administration: Intravenous, Subcutaneous, Oral, and Enteral By Intravenous Type: PN and Injectables By End User: Hospitals (Acute Care), Home Care (HPN Programs), ICU Settings, Specialty GI Centers, and Pediatric Specialty Hospitals By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy, and Online Pharmacy
Countries Covered	North America · U.S. · Canada · Mexico Europe · Germany · France · U.K. · Netherlands · Switzerland · Belgium · Russia · Italy · Spain · Turkey · Rest of Europe Asia-Pacific · China · Japan · India · South Korea · Singapore · Malaysia · Australia · Thailand · Indonesia · Philippines · Rest of Asia-Pacific Middle East and Africa · Saudi Arabia · U.A.E. · South Africa · Egypt · Israel · Rest of Middle East and Africa South America · Brazil · Argentina · Rest of South America
Key Market Players	· Takeda Pharmaceutical Company Limited (Japan) · Fresenius Kabi AG (Germany) · Baxter International Inc. (U.S.) · Nestlé Health Science (Switzerland) · Abbott Laboratories (U.S.) · Zealand Pharma A/S (Denmark) · Hanmi Pharm. Co., Ltd. (South Korea) · OxThera (Sweden) · AmeriPharma Specialty Care (U.S.) · ContinuumRx (U.S.) · Napo Therapeutics (Switzerland) · Eclipse Regenesis (U.S.) · AcuLife Healthcare Private Limited (India) · Ferring Pharmaceuticals (Switzerland) · Shandong Qidu Pharmaceutical Co., Ltd. (China) · Choice Parenteral Nutrition LLC (U.S.) · Integrated Care Systems (U.S.) · Beverly Hills Digestive Care (U.S.) · Stanford Health Care (U.S.) · Vision Parenteral (U.S.) · Amsino International, Inc. (U.S.) · Aculife Healthcare (India) · Nutrego (Netherlands) · Camvitaa (India) · Laboratoire Dielen (France) · Infusion Solutions (U.S.) · Aurora Health Care (U.S.)
Market Opportunities	· Advancements in Regenerative Medicine · Expansion of Home-Based Nutritional Care
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Trends

Trend: Complex Multidisciplinary Patient Management

Advancements in regenerative medicine and intestinal rehabilitation are creating strong growth opportunities for the global Type 1 SBS-IF treatment market. Researchers and healthcare institutions are increasingly focusing on therapies that can improve intestinal adaptation, regenerate damaged intestinal tissue, and reduce long-term dependence on parenteral nutrition. According to studies supported by the National Institutes of Health, regenerative approaches such as stem cell therapy, tissue engineering, and intestinal transplantation research are showing promising results in improving nutrient absorption and restoring bowel function in severe SBS-IF patients. Several academic hospitals and specialized intestinal rehabilitation centers in North America and Europe are also expanding multidisciplinary treatment programs that combine GLP-2 therapies, advanced nutritional support, surgery, and personalized rehabilitation plans. These developments are helping improve patient survival and quality of life while opening new long-term treatment opportunities beyond traditional nutritional management.

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Dynamics

Key Market Driver: Rising SBS-If Patient Population

The rising patient population suffering from Short Bowel Syndrome with Intestinal Failure (SBS-IF) is becoming one of the major growth drivers for the global treatment market. SBS-IF mainly develops when a large portion of the small intestine is removed through surgery, reducing the body’s ability to absorb nutrients and fluids properly. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the condition most commonly occurs after small bowel resection surgeries performed for diseases such as Crohn’s disease, intestinal cancers, trauma, bowel obstruction, ischemia, and congenital intestinal disorders. The growing incidence of inflammatory bowel diseases, especially Crohn’s disease, is significantly contributing to the increase in intestinal surgeries worldwide. NIDDK also states that severe Crohn’s disease patients often require repeated bowel resections, which raises the long-term risk of developing SBS-IF.

Key Restraint/Challenge: High Cost Of SBS-If Treatment

The high cost of SBS-IF treatment remains one of the biggest restraints for the global Type 1 SBS-IF treatment market. Patients with Short Bowel Syndrome with Intestinal Failure often require lifelong parenteral nutrition, frequent hospital monitoring, specialized intestinal rehabilitation, and advanced biologic therapies such as teduglutide. According to the U.S. Food and Drug Administration and Takeda treatment information, GLP-2 therapies like GATTEX can cost nearly USD 400,000–USD 500,000 annually per patient in the United States, making treatment financially difficult for many families and healthcare systems. In addition to drug costs, SBS-IF patients often need central venous catheter care, nutritional supplements, regular blood testing, and repeated hospital admissions due to infections or dehydration complications. These long-term medical expenses place a major burden on both patients and insurance providers, especially in countries where reimbursement coverage for rare diseases is still limited.

Key Market Opportunity: Expansion of advanced biologic and GLP-2 analog therapies.

The global Type 1 SBS-IF treatment market presents significant growth opportunities driven by continuous advancements in therapeutic and nutritional management approaches. Increasing adoption of innovative biologics, particularly GLP-2 analog therapies, is creating new avenues for improving intestinal adaptation and reducing dependence on parenteral nutrition. The growing focus on personalized nutrition plans and multidisciplinary care is enhancing patient outcomes and expanding treatment accessibility. Emerging economies offer substantial potential due to improving healthcare infrastructure, greater awareness of rare gastrointestinal disorders, and rising healthcare expenditure. Additionally, ongoing research in regenerative medicine, stem-cell-based therapies, and intestinal tissue engineering may transform future treatment paradigms. Expanding home-based care models and remote monitoring solutions are also expected to improve long-term disease management and patient quality of life.

Type 1 SBS-IF treatment market Scope

The Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into notable segments based on treatment modality, market attribution, disease management phase, patient type, route of administration, end user, distribution channel.

By treatment modality

On the basis of treatment modality, the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into nutritional support therapy, pharmacological therapy, surgical & interventional treatment, and emerging & advanced therapies. In 2026, the nutritional support therapy segment is expected to dominate the market with share of 42.00% due to the critical dependence of Type 1 SBS-IF patients on nutritional rehabilitation and long-term intestinal support therapies for maintaining hydration, nutrient absorption, and overall metabolic stability

The Emerging & Advanced Therapies segment is anticipated to witness the fastest CAGR of 7.7% from 2026 to 2033, fueled by increasing research and development activities focused on innovative gastrointestinal treatments, regenerative medicine, and peptide-based therapies for short bowel syndrome with intestinal failure (SBS-IF). Growing adoption of advanced biologics, rising clinical trial investments, and the increasing demand for therapies that reduce dependence on long-term parenteral nutrition are further accelerating the growth of this segment across developed and emerging healthcare markets.

By Market attribution

On the basis of market attribution, the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into core SBS-IF market, SBS-IF attributable market, and adjacent/non-specific market. In 2026, the core SBS-IF market segment is expected to dominate the market with 56.72% due to the high clinical dependence on specialized nutritional therapies and targeted intestinal adaptation treatments directly associated with SBS-IF management.

The SBS-IF attributable market segment is expected to witness the fastest CAGR of 9.5% from 2026 to 2033, driven by the increasing prevalence of short bowel syndrome-associated intestinal failure and the rising demand for long-term nutritional and gastrointestinal support therapies. Growth is further supported by advancements in parenteral nutrition formulations, expanding availability of targeted therapeutics, and growing awareness regarding early diagnosis and specialized treatment approaches aimed at improving patient quality of life and reducing hospitalization rates.

By disease management phase

On the basis of disease management phase, the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into acute phase (Type 1 SBS-IF), adaptation phase, and recovery phase. In 2026, the acute phase (Type 1 SBS-IF) segment is expected to dominate the market with share of 48.46% due to the immediate requirement for intensive nutritional support, fluid stabilization, and hospitalization following intestinal dysfunction or surgical resection.

The Adaptation Phase segment is anticipated to witness the fastest CAGR of 7.6% from 2026 to 2033, driven by the increasing focus on intestinal rehabilitation therapies and advanced nutritional management strategies aimed at enhancing bowel adaptation and reducing long-term dependence on parenteral nutrition. Rising adoption of personalized treatment approaches, growing clinical awareness regarding early intervention, and continuous advancements in gastrointestinal therapeutics are further supporting the rapid growth of this segment during the forecast period.

By route of administration

On the basis of route of administration, the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into intravenous, subcutaneous, oral, and enteral. The intravenous segment is further segmented into PN and injectables. In 2026, the intravenous segment is expected to dominate the market with share of 49.45% due to the widespread utilization of parenteral nutrition and hospital-administered therapies in critically ill SBS-IF patients with compromised intestinal absorption capacity.

The subcutaneous segment is expected to witness the fastest CAGR of 7.6% from 2026 to 2033, fueled by the increasing preference for minimally invasive drug administration methods and the growing adoption of home-based treatment solutions among patients with Type 1 SBS-IF. In addition, advancements in subcutaneous delivery formulations, improved patient convenience, reduced hospital visits, and rising demand for long-term supportive care therapies are further accelerating the growth of this segment during the forecast period.

By end user

On the basis of end user, the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into hospitals (acute care), home care (HPN programs), ICU settings, specialty GI centers, and pediatric specialty hospitals. In 2026, the hospitals (acute care) segment is expected to dominate the market with share of 38.67% due to the high requirement for multidisciplinary treatment management, intensive nutritional monitoring, and specialized gastrointestinal care during the acute phase of SBS-IF treatment.

The Home Care (HPN Programs) segment is expected to witness the fastest CAGR of 7.9% from 2026 to 2033, fueled by the increasing preference for home-based healthcare solutions among patients requiring long-term parenteral nutrition support. Rising healthcare costs, advancements in portable infusion technologies, and growing emphasis on improving patient comfort and quality of life are further accelerating the adoption of home parenteral nutrition (HPN) programs globally.

By distribution channel

On the basis of distribution channel, the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into hospital pharmacy, specialty pharmacy, retail pharmacy, and online pharmacy. In 2026, the hospital pharmacy segment is expected to dominate the market with share of 46.37% due to the high volume of inpatient nutritional therapies, biologics, and injectable medications administered within hospital settings for SBS-IF management.

The Specialty Pharmacy segment is expected to witness the fastest CAGR of 7.7% from 2026 to 2033, fueled by the increasing demand for personalized treatment management, home-based infusion services, and long-term nutritional support therapies for patients suffering from Type 1 SBS-IF. Additionally, the growing adoption of specialty pharmacy services for efficient drug distribution, patient monitoring, reimbursement assistance, and improved adherence to complex therapeutic regimens is further accelerating segment growth during the forecast period.

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Regional Analysis

North America dominated the Type 1 SBS-IF treatment market and accounted for the largest revenue share of 41.37% in 2025, supported by advanced healthcare infrastructure, favorable reimbursement frameworks, and the strong presence of specialized intestinal rehabilitation centers. The region benefits from high awareness and early diagnosis of short bowel syndrome, widespread adoption of parenteral nutrition and advanced pharmacological therapies, and significant investments in rare disease research. Additionally, the availability of innovative biologic treatments, robust clinical trial activity, and strong regulatory support for orphan drugs have contributed to market growth. Increasing focus on improving patient outcomes, reducing long-term complications associated with intestinal failure, and expanding access to multidisciplinary care programs continues to reinforce North America’s leading position in the global Type 1 SBS-IF treatment market.

U.S. Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Insight

The U.S. Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) treatment market represents the largest share of the North American market, driven by advanced healthcare facilities, strong reimbursement coverage, and widespread availability of specialized intestinal rehabilitation programs. Increasing adoption of parenteral nutrition, innovative GLP-2 therapies, and ongoing rare disease research initiatives continues to support market growth and improve patient outcomes.

Europe Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Insight

The Europe Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) treatment market is experiencing steady growth, driven by well-established healthcare systems, increasing awareness of rare gastrointestinal disorders, and widespread availability of specialized intestinal rehabilitation services. Growing adoption of advanced nutritional support therapies, favorable orphan drug policies, and ongoing clinical research activities are supporting treatment innovation and improving patient outcomes across the region.

U.K. Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Insight

The U.K. Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) treatment market is supported by a well-established healthcare system, increasing adoption of specialized nutritional therapies, and growing access to multidisciplinary intestinal rehabilitation services. Rising awareness of rare gastrointestinal disorders, favorable clinical guidelines, and ongoing advancements in biologic treatments are contributing to improved patient management and market growth across the country.

Germany Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Insight

Germany represents a significant market for Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) treatment, driven by its advanced healthcare system, strong reimbursement coverage, and well-established network of specialized gastroenterology and intestinal rehabilitation centers. Increasing adoption of parenteral nutrition, growing access to innovative therapies, and ongoing clinical research activities are supporting improved patient management and contributing to market growth across the country.

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Insight

The Asia-Pacific Type 1 SBS-IF treatment market is expected to witness the fastest growth, registering a CAGR during the forecast period. Growth is driven by improving healthcare infrastructure, increasing awareness of rare gastrointestinal disorders, expanding access to specialized nutritional therapies, and rising healthcare expenditure. Countries such as China, Japan, India, and South Korea are investing in advanced treatment options and intestinal rehabilitation services, supporting market expansion across the region.

Japan Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Insight

The Japan Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) treatment market is witnessing steady growth due to the country's advanced healthcare system, increasing prevalence of gastrointestinal disorders requiring intestinal resection, and strong focus on rare disease management. Growing adoption of specialized nutritional support therapies, improved access to innovative treatments, and expanding intestinal rehabilitation programs are contributing to enhanced patient care and market development.

China Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Insight

The China Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) treatment market is experiencing steady growth, driven by improving healthcare infrastructure, increasing awareness of rare gastrointestinal disorders, and expanding access to specialized nutritional support therapies. Rising investments in advanced medical care, growing adoption of intestinal rehabilitation programs, and enhanced diagnostic capabilities are supporting market development. Additionally, government efforts to strengthen rare disease management and healthcare accessibility are creating favorable conditions for the adoption of innovative SBS-IF treatment approaches.

Type 1 SBS-IF treatment market Share

The Type 1 SBS-IF treatment industry is primarily led by well-established companies, including:

Takeda Pharmaceutical Company Limited (Japan)
Fresenius Kabi AG (Germany)
Baxter International Inc. (U.S.)
Nestlé Health Science (Switzerland)
Abbott Laboratories (U.S.)
Zealand Pharma A/S (Denmark)
Hanmi Pharm. Co., Ltd. (South Korea)
OxThera (Sweden)
AmeriPharma Specialty Care (U.S.)
ContinuumRx (U.S.)
Napo Therapeutics (Switzerland)
Eclipse Regenesis (U.S.)
AcuLife Healthcare Private Limited (India)
Ferring Pharmaceuticals (Switzerland)
Shandong Qidu Pharmaceutical Co., Ltd. (China)
Choice Parenteral Nutrition LLC (U.S.)
Integrated Care Systems (U.S.)
Beverly Hills Digestive Care (U.S.)
Stanford Health Care (U.S.)
Vision Parenteral (U.S.)
Amsino International, Inc. (U.S.)
Aculife Healthcare (India)
Nutrego (Netherlands)
Camvitaa (India)
Laboratoire Dielen (France)
Infusion Solutions (U.S.)
Aurora Health Care (U.S.)

Latest Developments in Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market

In 2026, Takeda Pharmaceutical Company Limited continued expanding its gastrointestinal disease and rare disorder therapeutic portfolio through investments in biologics, gastrointestinal innovation, and advanced intestinal disorder treatment research, reinforcing its long-term strategic position in the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market.
In 2026, Abbott Laboratories continued focusing on advanced clinical nutrition and gastrointestinal care solutions through ongoing innovation in specialized nutritional formulations and hospital-based nutrition support therapies, strengthening its position in the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market.
In March 2026, Nestlé Health Science introduced innovative medical nutrition solutions and strengthened its nutrition and health science integration strategy to expand its clinical nutrition and gastrointestinal health portfolio, supporting growth opportunities in the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market. 2026, Unilever announced the acquisition of U.S.-based supplement brand Grüns to expand its wellness and health portfolio. This development strengthens Unilever’s position in the growing nutraceutical and cosmeceutical segments.
In April 2026, Baxter International showcased recent innovations at the AORN Global Surgical Conference & Expo 2026 and continued expanding its nutritional care and connected healthcare technologies portfolio, reinforcing its presence in critical care and SBS-IF-related treatment solutions.
In April 2026, Fresenius Kabi AG highlighted its expanding clinical nutrition and infusion therapy portfolio through continued investments in advanced healthcare technologies and biologic treatment solutions, strengthening its position in the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market.

SKU-76247

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 DBMR MARKET POSITION GRID

2.7 VENDOR SHARE ANALYSIS

2.8 MULTIVARIATE MODELING

2.9 PRODUCT TYPE TIMELINE CURVE

2.1 MARKET APPLICATION COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.1.1 INTRODUCTION

4.1.2 POLITICAL ANALYSIS

4.1.3 ECONOMIC ANALYSIS

4.1.4 SOCIAL ANALYSIS

4.1.5 TECHNOLOGICAL ANALYSIS

4.1.6 ENVIRONMENTAL ANALYSIS

4.1.7 LEGAL ANALYSIS

4.1.8 CONCLUSION

4.2 PORTER’S FIVE FORCES ANALYSIS

4.2.1 INTRODUCTION

4.2.2 INTENSITY OF COMPETITIVE RIVALRY (HIGH)

4.2.3 BARGAINING POWER OF BUYERS – HIGH

4.2.4 THREAT OF NEW ENTRANTS – MODERATE

4.2.5 THREAT OF SUBSTITUTE PRODUCTS – MODERATE

4.2.6 BARGAINING POWER OF SUPPLIERS – MODERATE

4.2.7 CONCLUSION

4.3 COMPANY EVALUATION QUADRANT

4.4 PATIENT FUNNEL METHODOLOGY (MANDATORY MODEL)

4.4.1 A BOTTOM-UP PATIENT FUNNEL WILL BE CONSTRUCTED

4.4.1.1 TOTAL SBS POPULATION

4.4.1.2 SBS-IF POPULATION

4.4.1.3 DIAGNOSED SBS-IF PATIENTS

4.4.1.4 TREATED SBS-IF PATIENTS

4.4.1.5 THERAPY-SPECIFIC PATIENT POOLS

4.4.1.6 THIS ENSURES PATIENT NUMBERS ARE DIRECTLY ESTIMATED, NOT INFERRED FROM MARKET SIZE

4.4.1.7 GLOBAL PATIENT FUNNEL SEGMENTATION

4.4.1.8 TOTAL SBS POPULATION

4.4.1.9 ADULT SBS

4.4.1.10 PEDIATRIC SBS

4.4.1.11 SBS-IF POPULATION

4.4.1.12 TYPE 1 SBS-IF (ACUTE)

4.4.1.13 TYPE 2 SBS-IF (PROLONGED ACUTE)

4.4.1.14 TYPE 3 SBS-IF (CHRONIC)

4.4.1.15 DIAGNOSED PATIENT POPULATION

4.4.1.16 DIAGNOSED – HOSPITAL-BASED

4.4.1.17 DIAGNOSED – OUTPATIENT FOLLOW-UP

4.4.1.18 UNDIAGNOSED / MISCLASSIFIED

4.4.1.19 TREATED PATIENT POPULATION

4.4.1.20 ACTIVELY TREATED PATIENTS

4.4.1.21 UNTREATED / SUPPORTIVE-ONLY

4.4.2 TREATMENT-SPECIFIC PATIENT SEGMENTATION (CRITICAL)

4.4.2.1 PN-DEPENDENT PATIENT POPULATION (CORE SEGMENT)

4.4.2.2 FULLY PN-DEPENDENT

4.4.2.3 PARTIALLY PN-DEPENDENT

4.4.2.4 ICU PN-DEPENDENT (TYPE 1 ACUTE)

4.4.2.5 HOME PN-DEPENDENT

4.4.2.6 GLP-2 ANALOGUE TREATED PATIENTS

4.4.2.7 INCLUDES PATIENTS RECEIVING TEDUGLUTIDE

4.4.2.8 PIPELINE THERAPIES (E.G., APRAGLUTIDE)

4.4.2.9 SUB-SEGMENTATION

4.4.2.10 PN-DEPENDENT RECEIVING GLP-2

4.4.2.11 PN-WEANING PATIENTS

4.4.2.12 PEDIATRIC VS ADULT

4.4.2.13 SUPPORTIVE PHARMACOTHERAPY PATIENTS (ATTRIBUTABLE)

4.4.2.14 ANTI-DIARRHEAL USERS

4.4.2.15 PPI USERS

4.4.2.16 ANTIBIOTIC (SIBO) PATIENTS

4.4.2.17 MICRONUTRIENT-DEPENDENT PATIENTS

4.4.2.18 SURGICAL & TRANSPLANT PATIENTS

4.4.2.19 INTESTINAL LENGTHENING PROCEDURES

4.4.2.20 TRANSPLANT PATIENTS

4.4.2.21 POST-TRANSPLANT SURVIVORS

4.4.3 PATIENT SEGMENTATION BY DEPENDENCY STATUS (HIGHLY IMPORTANT)

4.4.3.1 PN-DEPENDENT POPULATION

4.4.3.2 CORE REVENUE-DRIVING SEGMENT

4.4.3.3 PN-WEANING POPULATION

4.4.3.4 GLP-2 RESPONDERS

4.4.3.5 PN-INDEPENDENT POPULATION

4.4.3.6 MAINTAINED ON ORAL/ENTERAL THERAPY

4.4.4 PATIENT SEGMENTATION BY DISEASE PHASE (TYPE 1 FOCUS)

4.4.4.1 ACUTE PHASE (TYPE 1 SBS-IF)

4.4.4.2 ICU-MANAGED PATIENTS

4.4.4.3 HIGH PN UTILIZATION

4.4.4.4 ADAPTATION PHASE

4.4.4.5 TRANSITION TO ENTERAL NUTRITION

4.4.4.6 INITIATION OF GLP-2 THERAPY

4.4.4.7 RECOVERY / STABILIZATION PHASE

4.4.4.8 REDUCED PN DEPENDENCY

4.4.4.9 LONG-TERM MAINTENANCE

4.4.4.10 PATIENT SEGMENTATION BY CARE SETTING

4.4.4.11 HOSPITAL-BASED PATIENTS

4.4.4.12 ICU

4.4.4.13 SURGICAL WARDS

4.4.4.14 HOME CARE PATIENTS

4.4.4.15 HOME PARENTERAL NUTRITION (HPN)

4.4.4.16 SPECIALTY CENTERS

4.4.4.17 INTESTINAL REHABILITATION CENTERS

4.4.5 PATIENT SEGMENTATION BY DEMOGRAPHICS

4.4.5.1 AGE GROUP

4.4.5.2 NEONATES

4.4.5.3 PEDIATRIC

4.4.5.4 ADULTS

4.4.5.5 GERIATRIC

4.4.5.6 GENDER

4.4.5.7 MALE

4.4.5.8 FEMALE

4.4.6 PATIENT SEGMENTATION BY ETIOLOGY

4.4.6.1 ADULT ETIOLOGY

4.4.6.2 CROHN'S DISEASE

4.4.6.3 MESENTERIC ISCHEMIA

4.4.6.4 SURGICAL RESECTIONS

4.4.6.5 ONCOLOGY-RELATED

4.4.6.6 PEDIATRIC ETIOLOGY

4.4.6.7 NECROTIZING ENTEROCOLITIS (NEC)

4.4.6.8 CONGENITAL DEFECTS (ATRESIA, GASTROSCHISIS)

4.4.7 GEOGRAPHIC PATIENT DISTRIBUTION

4.4.7.1 NORTH AMERICA

4.4.7.2 U.S.

4.4.7.3 CANADA

4.4.7.4 EUROPE

4.4.7.5 GERMANY

4.4.7.6 FRANCE

4.4.7.7 UK

4.4.7.8 ITALY

4.4.7.9 SPAIN

4.4.7.10 ASIA-PAIFIC

4.4.7.11 JAPAN

4.4.7.12 CHINA

4.4.7.13 INDIA

4.4.8 TREATMENT PENETRATION & UTILIZATION RATES

4.4.8.1 PN PENETRATION RATE

4.4.8.2 % OF SBS-IF PATIENTS ON PN

4.4.8.3 GLP-2 PENETRATION RATE

4.4.8.4 % OF ELIGIBLE PATIENTS RECEIVING GLP-2

4.4.8.5 SUPPORTIVE THERAPY PENETRATION

4.4.8.6 ANTI-DIARRHEAL USAGE RATE

4.4.8.7 PPI USAGE RATE

4.4.8.8 PATIENT-LEVEL COST MODELING

4.4.8.9 ANNUAL COST PER PATIENT

4.4.8.10 PN COST (HOSPITAL VS HOME)

4.4.8.11 GLP-2 THERAPY COST

4.4.8.12 SUPPORTIVE THERAPY COST

4.4.9 COST BY PATIENT TYPE

4.4.9.1 PN-DEPENDENT

4.4.9.2 GLP-2 TREATED

4.4.9.3 TRANSPLANT

4.4.9.4 OUTPUT DELIVERABLES (EXCEL – CLIENT CRITICAL)

4.4.9.5 TOTAL SBS-IF PATIENTS (BY COUNTRY)

4.4.9.6 DIAGNOSED VS TREATED PATIENTS

4.4.9.7 PN-DEPENDENT PATIENTS

4.4.9.8 GLP-2 TREATED PATIENTS

4.4.9.9 TREATMENT PENETRATION RATES

4.4.9.10 AVERAGE ANNUAL COST PER THERAPY

4.5 INDUSTRY INSIGHTS

4.5.1 INTRODUCTION

4.5.2 INDUSTRY STRUCTURE OVERVIEW

4.5.3 MICRO AND MACRO ECONOMIC FACTORS

4.5.4 PENETRATION AND GROWTH PROSPECT MAPPING

4.5.5 KEY PRICING STRATEGIES

4.5.6 INTERVIEWS WITH SPECIALISTS

4.5.7 ANALYSIS AND RECOMMENDATION

4.5.8 CONCLUSION

4.6 WAR-DRIVEN DISRUPTION IN PHARMACEUTICAL SUPPLY CHAINS, GEOGRAPHIC FOOTPRINTS, STRUCTURAL CHANGES, AND ADAPTIVE STRATEGIES

4.6.1 INTRODUCTION

4.6.2 SUPPLY CHAIN RESILIENCE

4.6.2.1 DIVERSIFICATION OF INGREDIENT AND PN/DRUG SUPPLIERS

4.6.2.2 ESTABLISHMENT OF REGIONAL PRODUCTION HUBS

4.6.2.3 STRATEGIC STOCKPILING OF CRITICAL PN BAGS, GLP-2 ANALOGUES, AND MEDICAL DEVICES

4.6.2.4 DEVELOPMENT OF ALTERNATIVE LOGISTICS AND COLD CHAIN ROUTES

4.6.2.5 STRATEGIC PARTNERSHIPS WITH LEADING CDMOS (E.G., CATALENT, LONZA)

4.6.2.6 EXPANSION OF MANUFACTURING, FILL-FINISH, AND PACKAGING CAPABILITIES FOR PN & GLP-2

4.6.3 ENERGY & MANUFACTURING OPERATIONAL COST RISK

4.6.3.1 RISING ENERGY COSTS IN PARENTERAL NUTRITION & DRUG FACILITIES

4.6.3.2 INCREASED COSTS FOR RAW MATERIALS, LIPID EMULSIONS, AND PHARMACEUTICALS

4.6.3.3 LONG-TERM ENERGY PROCUREMENT STRATEGIES FOR PN MANUFACTURERS

4.6.3.4 ADOPTION OF ENERGY-EFFICIENT MANUFACTURING TECHNOLOGIES

4.6.3.5 DEPLOYMENT OF ADVANCED AUTOMATION AND CONTINUOUS SYSTEMS

4.6.3.6 INTEGRATION OF RENEWABLE ENERGY IN MANUFACTURING FACILITIES

4.6.4 GEOGRAPHIC FOOTPRINT REASSESSMENT

4.6.4.1 EXPANSION OF MANUFACTURING IN STABLE REGIONS

4.6.4.2 DIVERSIFICATION OF GLOBAL PN/GLP-2 PRODUCTION SITES

4.6.4.3 RELOCATION OF KEY INPUT/INTERMEDIATE PRODUCTION

4.6.4.4 EXPANSION INTO EMERGING MARKETS WITH HIGH SBS-IF BURDEN

4.6.4.5 ESTABLISHMENT OF REGIONAL COLD CHAIN TRANSIT AND DISTRIBUTION HUBS

4.6.5 SCENARIO PLANNING & RISK MANAGEMENT

4.6.5.1 DEVELOPMENT OF SUPPLY CHAIN CONTINGENCY PLANS

4.6.5.2 MULTI-SOURCE PROCUREMENT STRATEGIES FOR PN/GLP-2

4.6.5.3 GOVERNMENT AND HEALTH AUTHORITY COLLABORATIONS

4.6.5.4 CRISIS-RESPONSE SUPPLY NETWORKS FOR CRITICAL THERAPIES

4.6.5.5 DEPLOYMENT OF PREDICTIVE SUPPLY CHAIN ANALYTICS IN SBS-IF MARKET

4.6.6 CASH & FINANCIAL PROTECTION

4.6.7 STRENGTHENING CAPITAL RESERVES FOR PN & BIOPHARMA EXPANSION

4.6.7.1 DIVERSIFICATION OF PRODUCT PORTFOLIOS AND REVENUE STREAMS

4.6.7.2 INVESTMENTS IN DOMESTIC PRODUCTION INFRASTRUCTURE

4.6.7.3 GOVERNMENT INCENTIVES AND PUBLIC-PRIVATE PARTNERSHIPS

4.6.7.4 LONG-TERM PROCUREMENT CONTRACTS WITH HEALTHCARE SYSTEMS

4.6.8 DATA PROTECTION

4.6.8.1 DATA PROTECTION FRAMEWORKS FOR CLINICAL AND REAL-WORLD SBS-IF DATA

4.6.8.2 PROTECTION OF CLINICAL TRIAL DATA, PATIENT DATA, AND DRUG DEVELOPMENT

4.6.8.3 SECURE CLOUD INFRASTRUCTURE FOR SBS-IF DATA MANAGEMENT

4.6.8.4 AI-DRIVEN THREAT DETECTION IN MARKET RESEARCH AND PHARMA NETWORKS

4.6.8.5 COMPLIANCE WITH PHARMACEUTICAL DATA REGULATIONS & GXP

4.6.9 NEW BUSINESS AND EMERGING REVENUE OPPORTUNITIES & FUTURE OUTLOOK

4.6.10 CONCLUSION

4.7 EPIDEMIOLOGY

4.7.1 INTRODUCTION

4.7.2 INCIDENCE OF TYPE 1 SBS-IF BY GENDER

4.7.3 TREATMENT RATE

4.7.4 MORTALITY RATE

4.7.5 TREATMENT ADHERENCE AND SWITCH MODEL

4.7.6 PATIENT TREATMENT SUCCESS RATES

4.7.7 CONCLUSION

4.8 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE GLOBAL TYPE 1 SBS-IF MARKET

4.9 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE – GLOBAL TYPE 1 SBS-IF MARKET

4.1 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE – GLOBAL TYPE 1 SBS-IF MARKET

4.11 PIPELINE ANALYSIS

4.11.1 INTRODUCTION

4.11.2 CLINICAL TRIALS AND PHASE ANALYSIS

4.11.3 DRUG & BIOTHERAPY PIPELINE

4.11.4 PHASE III CANDIDATES (E.G., APRAGLUTIDE)

4.11.5 PHASE II CANDIDATES (E.G., LONG-ACTING GLP-2)

4.11.6 PHASE I CANDIDATES (EMERGING REGENERATIVE/CELLULAR)

4.11.7 OTHERS (PRE-CLINICAL, EN FORMULATION PIPELINE)

4.11.8 CONCLUSION

4.12 PIPELINE ANALYSIS

4.12.1 INTRODUCTION

4.12.2 TAKEDA PHARMACEUTICAL COMPANY – R&D LEADERSHIP IN INTESTINAL REGENERATION THERAPIES

4.12.3 BAXTER INTERNATIONAL – PARENTERAL NUTRITION AND INFUSION SYSTEM INNOVATION

4.12.4 FRESENIUS KABI AG – CLINICAL NUTRITION AND INJECTABLE THERAPY DEVELOPMENT

4.12.5 NESTLÉ HEALTH SCIENCE – MEDICAL NUTRITION AND GUT ADAPTATION RESEARCH

4.12.6 ABBOTT LABORATORIES – INTEGRATED NUTRITION AND METABOLIC MONITORING SOLUTIONS

4.12.7 CONCLUSION

4.13 MARKETED THERAPY ANALYSIS

4.13.1 INTRODUCTION

4.13.2 DRUG/THERAPY

4.13.2.1 BRAND NAME

4.13.2.2 GENERICS NAME

4.13.3 PHARMACOLOGICAL CLASSIFICATION

4.13.4 PRIMARY INDICATION

4.13.5 MARKET STATUS

4.13.6 MEDICATION TYPE

4.13.7 DOSAGE FORM

4.13.8 DOSAGE AVAILABILITY

4.13.9 PACKAGING TYPE

4.13.10 ROUTE OF ADMINISTRATION

4.13.11 DOSING FREQUENCY

4.13.12 THERAPY INSIGHT

4.13.13 AN OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES, REGULATORY MILESTONES, SAFETY/EFFICACY, MARKET EXCLUSIVITY DATA

4.13.14 FORECAST MARKET OUTLOOK

4.13.14.1 CROSS COMPETITION

4.13.14.2 THERAPEUTIC PORTFOLIO

4.13.14.3 CURRENT DEVELOPMENT SCENARIO

4.13.15 CONCLUSION

4.14 PIPELINE ANALYSIS - GLOBAL TYPE 1 SBS-IF TREATMENT MARKET

4.14.1 CLINICAL TRIALS AND PHASE ANALYSIS

4.14.2 DRUG AND BIOTHERAPY PIPELINE

4.14.3 PHASE III CANDIDATES

4.14.4 PHASE II CANDIDATES

4.14.5 PHASE I CANDIDATES

4.14.6 OTHERS (PRE-CLINICAL AND RESEARCH STAGE)

4.15 R & D ANALYSIS

4.15.1 COMPARATIVE ANALYSIS

4.15.2 DEVELOPMENTAL LANDSCAPE

4.15.3 INSIGHTS ON REGULATORY MILESTONES

4.15.4 THERAPEUTIC ASSESSMENT

4.15.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

5 HEALTHCARE TARIFFS IMPACT ANALYSIS

5.1 OVERVIEW

5.2 TARIFF STRUCTURES

5.2.1 GLOBAL VS. REGIONAL TARIFF STRUCTURES

5.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES

5.2.3 ASIA-PACIFIC: GOVERNMENT TARIFFS ON IMPORTED PN/DRUG THERAPIES

5.2.4 EMERGING MARKETS: TARIFF CHALLENGES FOR NUTRITION & BIOLOGICS

5.2.5 MAJOR MARKET UPTAKE

5.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS

5.3.1 IMPORT DUTIES ON PN KITS, GLP-2 VS. GENERICS

5.3.2 IMPACT ON AFFORDABILITY & ACCESS

5.3.3 KEY TRADE AGREEMENTS AFFECTING SBS-IF PRODUCTS

5.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS/PATIENTS

5.4.1 COST BURDEN ON HOSPITALS AND FACILITIES

5.4.2 EFFECT ON PATIENT AFFORDABILITY & INSURANCE COVERAGE

5.4.3 ROLE IN MEDICAL TOURISM FOR ADVANCED SBS-IF THERAPIES

5.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS

5.5.1 WTO REGULATIONS

5.5.2 TRADE WARS IMPACT ON SUPPLY CHAIN

5.5.3 FTAS IN REDUCING TARIFFS

5.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY

5.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR

6 MARKET ACCESS

6.1 10-YEAR MARKET FORECAST

6.2 CLINICAL TRIAL RECENT UPDATES

6.3 ANNUAL NEW FDA APPROVALS FOR SBS-IF TREATMENTS

6.4 MANUFACTURERS, DISTRIBUTORS, AND DEALS

6.5 MAJOR MARKET UPTAKE

6.6 CURRENT TREATMENT PRACTICES

6.7 IMPACT OF UPCOMING THERAPIES

7 REGULATORY FRAMEWORK–

7.1 INTRODUCTION

7.2 REGULATORY APPROVAL PROCESS

7.3 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

7.4 REGULATORY APPROVAL PATHWAYS

7.5 LICENSING AND REGISTRATION

7.6 POST-MARKETING SURVEILLANCE

7.7 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

7.8 CONCLUSION

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING SBS-IF PATIENT POPULATION

8.1.2 GROWING ADOPTION OF GLP-2 THERAPIES

8.1.3 INCREASING GOVERNMENT & ORPHAN DRUG SUPPORT

8.2 RESTRAINTS

8.2.1 HIGH COST OF SBS-IF TREATMENT

8.2.2 LIMITE.D AWARENESS & DELAYED DIAGNOSIS

8.3 OPPORTUNITIES

8.3.1 COMPLEX MULTIDISCIPLINARY PATIENT MANAGEMENT

8.3.2 STRINGENT REGULATORY APPROVAL PROCESSES

8.4 CHALLENGES

8.4.1 ADVANCEMENTS IN REGENERATIVE MEDICINE

8.4.2 EXPANSION OF HOME-BASED NUTRITIONAL CARE

9 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY

9.1 OVERVIEW

9.2 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

9.2.1 NUTRITIONAL SUPPORT THERAPY

9.2.2 PHARMACOLOGICAL THERAPY

9.2.3 SURGICAL & INTERVENTIONAL TREATMENT

9.2.4 EMERGING & ADVANCED THERAPIES

9.3 GLOBAL NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.3.1 PARENTERAL NUTRITION (PN)

9.3.2 ENTERAL NUTRITION (EN)

9.3.3 PN COMPOSITION

9.4 GLOBAL PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.4.1 HOME PARENTERAL NUTRITION (HPN)

9.4.2 PERIPHERAL PARENTERAL NUTRITION (PPN)

9.4.3 CYCLIC PARENTERAL NUTRITION

9.5 GLOBAL TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.5.1 HOSPITAL-BASED TPN

9.5.2 ICU-BASED TPN

9.6 GLOBAL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

9.6.1 ADULT HPN

9.6.2 PEDIATRIC HPN

9.7 GLOBAL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

9.7.1 LONG-TERM HPN

9.7.2 SHORT-TERM HPN

9.8 GLOBAL ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.8.1 ORAL FEEDING

9.8.2 TUBE FEEDING

9.8.3 FORMULA TYPE

9.9 GLOBAL TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.9.1 NASOGASTRIC (NG)

9.9.2 PEG FEEDING

9.9.3 JEJUNOSTOMY FEEDING

9.1 GLOBAL FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.10.1 POLYMERIC

9.10.2 ELEMENTAL

9.10.3 SEMI-ELEMENTAL

9.11 GLOBAL PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.11.1 MACRONUTRIENTS

9.11.2 ELECTROLYTES & FLUIDS

9.11.3 MICRONUTRIENTS

9.12 GLOBAL MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.12.1 AMINO ACIDS

9.12.2 LIPID EMULSIONS

9.12.3 DEXTROSE

9.13 GLOBAL MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.13.1 VITAMINS

9.13.2 TRACE ELEMENTS

9.14 GLOBAL NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.14.1 NORTH AMERICA

9.14.2 EUROPE

9.14.3 ASIA-PACIFIC

9.14.4 MIDDLE EAST AND AFRICA

9.14.5 SOUTH AMERICA

9.15 GLOBAL PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.15.1 HORMONAL & INTESTINAL ADAPTATION THERAPY

9.15.2 ANTI-DIARRHEAL THERAPY

9.15.3 ANTI-SECRETORY THERAPY

9.15.4 MICRONUTRIENT SUPPLEMENTATION

9.15.5 ANTI-INFECTIVE THERAPY

9.15.6 BILE ACID & ABSORPTION MODIFIERS

9.16 GLOBAL HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.16.1 GLP-2 ANALOGUES

9.16.2 GROWTH HORMONE THERAPY

9.16.3 IGF-1 & ANALOGUES

9.17 GLOBAL GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.17.1 TEDUGLUTIDE

9.17.2 APRAGLUTIDE (LATE-STAGE)

9.17.3 LONG-ACTING GLP-2 ANALOGUES

9.18 GLOBAL GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

9.18.1 HUMATROPE

9.18.2 NORDITROPIN

9.18.3 GENOTROPIN

9.19 GLOBAL IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.19.1 INCRELEX

9.19.2 OTHERS

9.2 GLOBAL ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.20.1 OPIOID-BASED

9.20.2 NON-OPIOID AGENTS

9.21 GLOBAL OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.21.1 LOPERAMIDE

9.21.2 CODEINE

9.22 GLOBAL ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.22.1 PROTON PUMP INHIBITORS

9.22.2 SOMATOSTATIN ANALOGUES

9.22.3 H2 RECEPTOR ANTAGONISTS

9.23 GLOBAL PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.23.1 OMEPRAZOLE

9.23.2 PANTOPRAZOLE

9.23.3 ESOMEPRAZOLE

9.23.4 OTHERS

9.24 GLOBAL SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

9.24.1 OCTREOTIDE

9.24.2 OTHERS

9.25 GLOBAL H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.25.1 FAMOTIDINE

9.25.2 OTHERS

9.26 GLOBAL MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.26.1 FAT-SOLUBLE VITAMINS (A, D, E, K)

9.26.2 ELECTROLYTES

9.26.3 VITAMIN B12

9.26.4 MINERAL SUPPLEMENTATION

9.27 GLOBAL ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.27.1 BROAD-SPECTRUM ANTIBIOTICS

9.27.2 SIBO-TARGETED THERAPY

9.28 GLOBAL BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.28.1 BILE ACID SEQUESTRANTS

9.28.2 FAT ABSORPTION ENHANCERS

9.29 GLOBAL BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.29.1 CHOLESTYRAMINE

9.29.2 COLESEVELAM

9.29.3 OTHERS

9.3 GLOBAL PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.30.1 NORTH AMERICA

9.30.2 EUROPE

9.30.3 ASIA-PACIFIC

9.30.4 MIDDLE EAST AND AFRICA

9.30.5 SOUTH AMERICA

9.31 GLOBAL SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.31.1 INTESTINAL LENGTHENING PROCEDURES

9.31.2 OSTOMY & RECONSTRUCTION

9.31.3 INTESTINAL TRANSPLANTATION

9.32 GLOBAL INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.32.1 STEP PROCEDURE

9.32.2 BIANCHI PROCEDURE

9.33 GLOBAL OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.33.1 ILEOSTOMY

9.33.2 JEJUNOSTOMY

9.33.3 REVERSAL SURGERY

9.34 GLOBAL INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.34.1 ISOLATED SMALL BOWEL

9.34.2 LIVER + INTESTINE

9.34.3 MULTIVISCERAL TRANSPLANT

9.35 GLOBAL SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.35.1 NORTH AMERICA

9.35.2 EUROPE

9.35.3 ASIA-PACIFIC

9.35.4 MIDDLE EAST AND AFRICA

9.35.5 SOUTH AMERICA

9.36 GLOBAL EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.36.1 REGENERATIVE MEDICINE

9.36.2 MICROBIOME-BASED THERAPY

9.36.3 GENE THERAPY

9.37 GLOBAL REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.37.1 STEM CELL THERAPY

9.37.2 TISSUE-ENGINEERED INTESTINE

9.38 GLOBAL MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.38.1 PROBIOTICS

9.38.2 FMT

9.39 GLOBAL GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.39.1 ABSORPTIVE FUNCTION TARGETING

9.39.2 MUCOSAL GROWTH MODULATION

9.4 GLOBAL EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.40.1 NORTH AMERICA

9.40.2 EUROPE

9.40.3 ASIA-PACIFIC

9.40.4 MIDDLE EAST AND AFRICA

9.40.5 SOUTH AMERICA

10 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION

10.1 OVERVIEW

10.2 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

10.2.1 CORE SBS-IF MARKET

10.2.2 SBS-IF ATTRIBUTABLE MARKET

10.2.3 ADJACENT / NON-SPECIFIC MARKET

10.3 GLOBAL CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

10.3.1 PARENTERAL NUTRITION

10.3.2 GLP-2 ANALOGUES

10.4 GLOBAL CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.4.1 NORTH AMERICA

10.4.2 EUROPE

10.4.3 ASIA-PACIFIC

10.4.4 MIDDLE EAST AND AFRICA

10.4.5 SOUTH AMERICA

10.5 GLOBAL SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

10.5.1 ANTI-DIARRHEALS

10.5.2 PPIS

10.5.3 ANTIBIOTICS

10.6 GLOBAL SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.6.1 NORTH AMERICA

10.6.2 EUROPE

10.6.3 ASIA-PACIFIC

10.6.4 MIDDLE EAST AND AFRICA

10.6.5 SOUTH AMERICA

10.7 GLOBAL ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.7.1 NORTH AMERICA

10.7.2 EUROPE

10.7.3 ASIA-PACIFIC

10.7.4 MIDDLE EAST AND AFRICA

10.7.5 SOUTH AMERICA

11 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE

11.1 OVERVIEW

11.2 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

11.2.1 ACUTE PHASE (TYPE 1 SBS-IF)

11.2.2 ADAPTATION PHASE

11.2.3 RECOVERY PHASE

11.3 GLOBAL ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.3.1 NORTH AMERICA

11.3.2 EUROPE

11.3.3 ASIA-PACIFIC

11.3.4 MIDDLE EAST AND AFRICA

11.3.5 SOUTH AMERICA

11.4 GLOBAL ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.4.1 NORTH AMERICA

11.4.2 EUROPE

11.4.3 ASIA-PACIFIC

11.4.4 MIDDLE EAST AND AFRICA

11.4.5 SOUTH AMERICA

11.5 GLOBAL RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.5.1 NORTH AMERICA

11.5.2 EUROPE

11.5.3 ASIA-PACIFIC

11.5.4 MIDDLE EAST AND AFRICA

11.5.5 SOUTH AMERICA

12 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE

12.1 OVERVIEW

12.2 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

12.2.1 ADULT

12.2.2 PEDIATRIC

12.3 GLOBAL ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

12.3.1 NORTH AMERICA

12.3.2 EUROPE

12.3.3 ASIA-PACIFIC

12.3.4 MIDDLE EAST AND AFRICA

12.3.5 SOUTH AMERICA

12.4 GLOBAL PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

12.4.1 NORTH AMERICA

12.4.2 EUROPE

12.4.3 ASIA-PACIFIC

12.4.4 MIDDLE EAST AND AFRICA

12.4.5 SOUTH AMERICA

13 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

13.2.1 INTRAVENOUS

13.2.2 SUBCUTANEOUS

13.2.3 ORAL

13.2.4 ENTERAL

13.3 GLOBAL INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

13.3.1 PN

13.3.2 INJECTABLES

13.4 GLOBAL INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.4.1 NORTH AMERICA

13.4.2 EUROPE

13.4.3 ASIA-PACIFIC

13.4.4 MIDDLE EAST AND AFRICA

13.4.5 SOUTH AMERICA

13.5 GLOBAL SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.5.1 NORTH AMERICA

13.5.2 EUROPE

13.5.3 ASIA-PACIFIC

13.5.4 MIDDLE EAST AND AFRICA

13.5.5 SOUTH AMERICA

13.6 GLOBAL ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.6.1 NORTH AMERICA

13.6.2 EUROPE

13.6.3 ASIA-PACIFIC

13.6.4 MIDDLE EAST AND AFRICA

13.6.5 SOUTH AMERICA

13.7 GLOBAL ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.7.1 NORTH AMERICA

13.7.2 EUROPE

13.7.3 ASIA-PACIFIC

13.7.4 MIDDLE EAST AND AFRICA

13.7.5 SOUTH AMERICA

14 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

14.2.1 HOSPITALS (ACUTE CARE)

14.2.2 HOME CARE (HPN PROGRAMS)

14.2.3 ICU SETTINGS

14.2.4 PECIALTY GI CENTERS

14.2.5 PEDIATRIC SPECIALTY HOSPITALS

14.3 GLOBAL HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.3.1 NORTH AMERICA

14.3.2 EUROPE

14.3.3 ASIA-PACIFIC

14.3.4 MIDDLE EAST AND AFRICA

14.3.5 SOUTH AMERICA

14.4 GLOBAL HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.4.1 NORTH AMERICA

14.4.2 EUROPE

14.4.3 ASIA-PACIFIC

14.4.4 MIDDLE EAST AND AFRICA

14.4.5 SOUTH AMERICA

14.5 GLOBAL ICU SETTINGS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.5.1 NORTH AMERICA

14.5.2 EUROPE

14.5.3 ASIA-PACIFIC

14.5.4 MIDDLE EAST AND AFRICA

14.5.5 SOUTH AMERICA

14.6 GLOBAL SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.6.1 NORTH AMERICA

14.6.2 EUROPE

14.6.3 ASIA-PACIFIC

14.6.4 MIDDLE EAST AND AFRICA

14.6.5 SOUTH AMERICA

14.7 GLOBAL PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.7.1 NORTH AMERICA

14.7.2 EUROPE

14.7.3 ASIA-PACIFIC

14.7.4 MIDDLE EAST AND AFRICA

14.7.5 SOUTH AMERICA

15 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

15.2.1 HOSPITAL PHARMACY

15.2.2 SPECIALTY PHARMACY

15.2.3 RETAIL PHARMACY

15.2.4 ONLINE PHARMACY

15.3 GLOBAL HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.3.1 NORTH AMERICA

15.3.2 EUROPE

15.3.3 ASIA-PACIFIC

15.3.4 MIDDLE EAST AND AFRICA

15.3.5 SOUTH AMERICA

15.4 GLOBAL SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.4.1 NORTH AMERICA

15.4.2 EUROPE

15.4.3 ASIA-PACIFIC

15.4.4 MIDDLE EAST AND AFRICA

15.4.5 SOUTH AMERICA

15.5 GLOBAL RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.5.1 NORTH AMERICA

15.5.2 EUROPE

15.5.3 ASIA-PACIFIC

15.5.4 MIDDLE EAST AND AFRICA

15.5.5 SOUTH AMERICA

16 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION

16.1 OVERVIEW

16.2 NORTH AMERICA

16.2.1 U.S.

16.2.2 CANADA

16.2.3 MEXICO

16.3 EUROPE

16.3.1 GERMANY

16.3.2 U.K

16.3.3 FRANCE

16.3.4 ITALY

16.3.5 SPAIN

16.3.6 TURKEY

16.3.7 RUSSIA

16.3.8 NETHERLANDS

16.3.9 SWITZERLAND

16.3.10 BELGIUM

16.3.11 SWEDEN

16.3.12 DENMARK

16.3.13 NORWAY

16.3.14 FINLAND

16.3.15 REST OF EUROPE

16.4 ASIA PACIFIC

16.4.1 JAPAN

16.4.2 CHINA

16.4.3 SOUTH KOREA

16.4.4 INDIA

16.4.5 SINGAPORE

16.4.6 THAILAND

16.4.7 INDONESIA

16.4.8 MALAYSIA

16.4.9 PHILIPPINES

16.4.10 BELGIUM

16.4.11 NEW ZEALAND

16.4.12 HONG KONG

16.4.13 TAIWAN

16.4.14 REST OF ASIA-PACIFIC

16.5 SOUTH AMERICA

16.5.1 BRAZIL

16.5.2 ARGENTINA

16.5.3 COLOMBIA

16.5.4 CHILE

16.5.5 PERU

16.5.6 ECUADOR

16.5.7 URUGUAY

16.5.8 VENEZUELA .

16.5.9 BOLIVIA

16.5.10 PARAGUAY

16.5.11 REST OF SOUTH AMERICA

16.6 MIDDLE EAST AND AFRICA

16.6.1 SAUDI ARABIA

16.6.2 SOUTH AFRICA

16.6.3 EGYPT

16.6.4 ISERAEL

16.6.5 UNITED ARAB EMIRATES

16.6.6 KUWAIT

16.6.7 OMAN

16.6.8 QATAR

16.6.9 BAHRAIN

16.6.10 REST OF MIDDLE EAST AND AFRICA

17 GLOBAL GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY LANDSCAPE

17.1 MANUFACTURER COMPANY SHARE ANALYSIS: GLOBAL

17.2 MANUFACTURER COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17.3 MANUFACTURER COMPANY SHARE ANALYSIS: EUROPE

17.4 MANUFACTURER COMPANY SHARE ANALYSIS: NORTH AMERICA

18 SWOT ANALYSIS

19 COMPANY PROFILES

19.1 FRESENIUS KABI

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 BAXTER INTERNATIONAL INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 NESTLÉ HEALTH SCIENCE

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 ABBOTT LABORATORIES

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 MOOG COMPANY

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT/NEWS

19.7 ACULIFE HEALTHCARE

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 AMSINO INTERNATIONAL, INC

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 AURORA HEALTH CARE

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 AMERIPHARMA SPECIALTY CARE.

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 BAUSCH HEALTH COMPANIES INC

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 BEVELRYHILLS DIGESTIVE CARE

19.12.1 COMPANY SNAPSHOT

19.12.2 PRODUCT PORTFOLIO

19.12.3 RECENT DEVELOPMENT

19.13 B. BRAUN SE

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 CAMVITTA

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 CHOICE PARENTERAL NUTRITION LLC

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENT

19.16 CONTINUUMRX

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 FERRING PHARMACEUTICALS

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENT

19.18 GRIFOLS S.A.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

19.19 HIKMA PHARMACEUTICALS

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENT

19.2 HOSPIRA (PART OF PFIZER INC.)

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

19.21 HANMI PHARM.CO.,LTD.

19.21.1 COMPANY SNAPSHOT

19.21.2 REVENUE ANALYSIS

19.21.3 PRODUCT PORTFOLIO

19.21.4 RECENT DEVELOPMENT

19.22 ICU MEDICAL, INC.

19.22.1 COMPANY SNAPSHOT

19.22.2 REVENUE ANALYSIS

19.22.3 PRODUCT PORTFOLIO

19.22.4 RECENT DEVELOPMENT

19.23 INFUSION SOLUTIONS

19.23.1 COMPANY SNAPSHOT

19.23.2 PRODUCT PORTFOLIO

19.23.3 RECENT DEVELOPMENT

19.24 INTEGRATED CARE SYSTEMS

19.24.1 COMPANY SNAPSHOT

19.24.2 PRODUCT PORTFOLIO

19.24.3 RECENT DEVELOPMENT

19.25 JEDUX PARENTERAL PRIVATE LIMITED

19.25.1 COMPANY SNAPSHOT

19.25.2 PRODUCT PORTFOLIO

19.25.3 RECENT DEVELOPMENT

19.26 LABORATOIRE DIELEN

19.26.1 COMPANY SNAPSHOT

19.26.2 PRODUCT PORTFOLIO

19.26.3 RECENT DEVELOPMENT

19.27 NAPO THERAPEUTICS.

19.27.1 COMPANY SNAPSHOT

19.27.2 PRODUCT PORTFOLIO

19.27.3 RECENT DEVELOPMENT/NEWS

19.28 NUTREGO

19.28.1 COMPANY SNAPSHOT

19.28.2 PRODUCT PORTFOLIO

19.28.3 RECENT DEVELOPMENT

19.29 NUTRICIA (DANONE GROUP)

19.29.1 COMPANY SNAPSHOT

19.29.2 REVENUE ANALYSIS

19.29.3 PRODUCT PORTFOLIO

19.29.4 RECENT DEVELOPMENT

19.3 NUTRICIA NORTH AMERICA

19.30.1 COMPANY SNAPSHOTS

19.30.2 PRODUCT PORTFOLIO

19.30.3 RECENT DEVELOPMENT

19.31 NUTRISHARE

19.31.1 COMPANY SNAPSHOT

19.31.2 PRODUCT PORTFOLIO

19.31.3 RECENT DEVELOPMENT

19.32 OXTHERA

19.32.1 COMPANY SNAPSHOT

19.32.2 PRODUCT PORTFOLIO

19.32.3 RECENT DEVELOPMENT

19.33 PHARMKO, INC.

19.33.1 COMPANY SNAPSHOT

19.33.2 PRODUCT PORTFOLIO

19.33.3 RECENT DEVELOPMENT

19.34 PUERTO LIFE SCIENCES PVT. LTD.

19.34.1 COMPANY SNAPSHOT

19.34.2 PRODUCT PORTFOLIO

19.34.3 RECENT DEVELOPMENT

19.35 SHANDONG QIDU PHARMACEUTICAL CO., LTD.

19.35.1 COMPANY SNAPSHOT

19.35.2 PRODUCT PORTFOLIO

19.35.3 RECENT DEVELOPMENT

19.36 STANFORD HEALTH CARE

19.36.1 COMPANY SNAPSHOT

19.36.2 PRODUCT PORTFOLIO

19.36.3 RECENT DEVELOPMENT

19.37 UF HEALTH

19.37.1 COMPANY SNAPSHOT

19.37.2 PRODUCT PORTFOLIO

19.37.3 RECENT DEVELOPMENT

19.38 IRONWOOD PHARMACEUTICALS

19.38.1 COMPANY SNAPSHOT

19.38.2 REVENUE ANALYSIS

19.38.3 PRODUCT PORTFOLIO

19.38.4 RECENT DEVELOPMENT

19.39 VISION PARENTERAL

19.39.1 COMPANY SNAPSHOT

19.39.2 PRODUCT PORTFOLIO

19.39.3 RECENT DEVELOPMENT

19.4 ZEALAND PHARMA

19.40.1 COMPANY SNAPSHOT

19.40.2 REVENUE ANALYSIS

19.40.3 PRODUCT PORTFOLIO

19.40.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

List of Table

TABLE 1 TREATMENT RATE OF SBI-IF PATIENTS

TABLE 2 ESTIMATED THERAPY-SPECIFIC PATIENT POOLS

TABLE 3 ESTIMATED FUNNEL PATEGINTS

TABLE 4 KEY INDUSTRY INSIGHTS AND MARKET TRENDS IN THE GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET

TABLE 5 IMPACT OF WAR-DRIVEN DISRUPTIONS ON THE GLOBAL TYPE 1 SBS-IF TREATMENT MARKET ECOSYSTEM AND INDUSTRY RESPONSE FRAMEWORK

TABLE 6 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE GLOBAL TYPE 1 SBS-IF MARKET

TABLE 7 DISTRIBUTION OF OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE – GLOBAL TYPE 1 SBS-IF MARKET

TABLE 8 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE – GLOBAL TYPE 1 SBS-IF MARKET

TABLE 9 PIPELINE LANDSCAPE AND CLINICAL DEVELOPMENT OVERVIEW

TABLE 10 TOP ENTITIES BASED ON R&D GLANCE – GLOBAL TYPE 1 SBS-IF TREATMENT MARKET

TABLE 11 PRECLINICAL / RESEARCH STAGE VACCINE CANDIDATES

TABLE 12 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 13 GLOBAL NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 14 GLOBAL PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 15 GLOBAL TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 16 GLOBAL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 17 GLOBAL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 18 GLOBAL ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 19 GLOBAL TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 20 GLOBAL FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 21 GLOBAL PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 22 GLOBAL MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 23 GLOBAL MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 24 GLOBAL NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 25 GLOBAL PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 26 GLOBAL HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 27 GLOBAL GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 28 GLOBAL GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 29 GLOBAL IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 30 GLOBAL ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 31 GLOBAL OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 32 GLOBAL ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 33 GLOBAL PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 34 GLOBAL SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 35 GLOBAL H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 36 GLOBAL MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 37 GLOBAL ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 38 GLOBAL BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 39 GLOBAL BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 40 GLOBAL PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 41 GLOBAL SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 42 GLOBAL INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 43 GLOBAL OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 44 GLOBAL INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 45 GLOBAL SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 46 GLOBAL EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 47 GLOBAL REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 48 GLOBAL MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 49 GLOBAL GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 50 GLOBAL EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 51 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 52 GLOBAL CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 53 GLOBAL CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 54 GLOBAL SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 55 GLOBAL SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 56 GLOBAL ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 57 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 58 GLOBAL ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 59 GLOBAL ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 60 GLOBAL RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 61 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 62 GLOBAL ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 63 GLOBAL PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 64 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 65 GLOBAL INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 66 GLOBAL INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 67 GLOBAL SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 68 GLOBAL ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 69 GLOBAL ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 70 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 71 GLOBAL HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 72 GLOBAL HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 73 GLOBAL ICU SETTINGS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 74 GLOBAL SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 75 GLOBAL PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 76 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 77 GLOBAL HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 78 GLOBAL SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 79 GLOBAL RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 80 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 81 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 82 GLOBAL NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 83 GLOBAL PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 84 GLOBAL TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 85 GLOBAL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 86 GLOBAL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 87 GLOBAL ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 88 GLOBAL TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 89 GLOBAL FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 90 GLOBAL PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 91 GLOBAL MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 92 GLOBAL MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 93 GLOBAL NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 94 GLOBAL PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 95 GLOBAL HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 96 GLOBAL GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 97 GLOBAL GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 98 GLOBAL IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 99 GLOBAL ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 100 GLOBAL OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 101 GLOBAL ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 102 GLOBAL PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 103 GLOBAL SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 104 GLOBAL H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 105 GLOBAL MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 106 GLOBAL ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 107 GLOBAL BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 108 GLOBAL BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 109 GLOBAL PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 110 GLOBAL SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 111 GLOBAL INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 112 GLOBAL OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 113 GLOBAL INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 114 GLOBAL SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 115 GLOBAL EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 116 GLOBAL REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 117 GLOBAL MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 118 GLOBAL GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 119 GLOBAL EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 120 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 121 GLOBAL CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 122 GLOBAL CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 123 GLOBAL SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 124 GLOBAL SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 125 GLOBAL ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 126 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 127 GLOBAL ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 128 GLOBAL ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 129 GLOBAL RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 130 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 131 GLOBAL ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 132 GLOBAL PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 133 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 134 GLOBAL INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 135 GLOBAL INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 136 GLOBAL SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 137 GLOBAL ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 138 GLOBAL ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 139 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 140 GLOBAL HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 141 GLOBAL HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 142 GLOBAL ICU SETTINGS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 143 GLOBAL SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 144 GLOBAL PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 145 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 146 GLOBAL HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 147 GLOBAL SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 148 GLOBAL RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 149 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)

TABLE 150 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 151 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 152 NORTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 153 NORTH AMERICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 154 NORTH AMERICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 155 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 156 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 157 NORTH AMERICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 158 NORTH AMERICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 159 NORTH AMERICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 160 NORTH AMERICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 161 NORTH AMERICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 162 NORTH AMERICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 163 NORTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 164 NORTH AMERICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 165 NORTH AMERICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 166 NORTH AMERICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 167 NORTH AMERICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 168 NORTH AMERICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 169 NORTH AMERICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 170 NORTH AMERICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 171 NORTH AMERICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 172 NORTH AMERICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 173 NORTH AMERICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 174 NORTH AMERICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 175 NORTH AMERICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 176 NORTH AMERICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 177 NORTH AMERICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 178 NORTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 179 NORTH AMERICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 180 NORTH AMERICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 181 NORTH AMERICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 182 NORTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 183 NORTH AMERICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 184 NORTH AMERICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 185 NORTH AMERICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 186 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 187 NORTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 188 NORTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 189 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 190 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 191 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 192 NORTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 193 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 194 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 195 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 196 US NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 197 US PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 198 US TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 199 US HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 200 US HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 201 US ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 202 US TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 203 US FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 204 US PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 205 US MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 206 US MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 207 US PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 208 US HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 209 US GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 210 US GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 211 US IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 212 US ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 213 US OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 214 US ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 215 US PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 216 US SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 217 US H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 218 US MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 219 US ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 220 US BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 221 US BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 222 US SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 223 US INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 224 US OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 225 US INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 226 US EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 227 US REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 228 US MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 229 US GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 230 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 231 US CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 232 US SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 233 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 234 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 235 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 236 US INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 237 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 238 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 239 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 240 CANADA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 241 CANADA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 242 CANADA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 243 CANADA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 244 CANADA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 245 CANADA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 246 CANADA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 247 CANADA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 248 CANADA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 249 CANADA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 250 CANADA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 251 CANADA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 252 CANADA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 253 CANADA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 254 CANADA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 255 CANADA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 256 CANADA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 257 CANADA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 258 CANADA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 259 CANADA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 260 CANADA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 261 CANADA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 262 CANADA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 263 CANADA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 264 CANADA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 265 CANADA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 266 CANADA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 267 CANADA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 268 CANADA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 269 CANADA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 270 CANADA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 271 CANADA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 272 CANADA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 273 CANADA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 274 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 275 CANADA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 276 CANADA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 277 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 278 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 279 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 280 CANADA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 281 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 282 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 283 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 284 MEXICO NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 285 MEXICO PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 286 MEXICO TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 287 MEXICO HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 288 MEXICO HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 289 MEXICO ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 290 MEXICO TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 291 MEXICO FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 292 MEXICO PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 293 MEXICO MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 294 MEXICO MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 295 MEXICO PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 296 MEXICO HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 297 MEXICO GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 298 MEXICO GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 299 MEXICO IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 300 MEXICO ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 301 MEXICO OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 302 MEXICO ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 303 MEXICO PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 304 MEXICO SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 305 MEXICO H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 306 MEXICO MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 307 MEXICO ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 308 MEXICO BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 309 MEXICO BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 310 MEXICO SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 311 MEXICO INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 312 MEXICO OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 313 MEXICO INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 314 MEXICO EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 315 MEXICO REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 316 MEXICO MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 317 MEXICO GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 318 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 319 MEXICO CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 320 MEXICO SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 321 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 322 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 323 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 324 MEXICO INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 325 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 326 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 327 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)

TABLE 328 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 329 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 330 EUROPE NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 331 EUROPE PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 332 EUROPE TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 333 EUROPE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 334 EUROPE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 335 EUROPE ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 336 EUROPE TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 337 EUROPE FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 338 EUROPE PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 339 EUROPE MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 340 EUROPE MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 341 EUROPE PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 342 EUROPE HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 343 EUROPE GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 344 EUROPE GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 345 EUROPE IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 346 EUROPE ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 347 EUROPE OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 348 EUROPE ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 349 EUROPE PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 350 EUROPE SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 351 EUROPE H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 352 EUROPE MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 353 EUROPE ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 354 EUROPE BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 355 EUROPE BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 356 EUROPE SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 357 EUROPE INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 358 EUROPE OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 359 EUROPE INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 360 EUROPE EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 361 EUROPE REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 362 EUROPE MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 363 EUROPE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 364 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 365 EUROPE CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 366 EUROPE SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 367 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 368 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 369 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 370 EUROPE INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 371 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 372 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 373 USD THOUSAND

TABLE 374 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 375 GERMANY NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 376 GERMANY PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 377 GERMANY TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 378 GERMANY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 379 GERMANY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 380 GERMANY ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 381 GERMANY TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 382 GERMANY FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 383 GERMANY PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 384 GERMANY MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 385 GERMANY MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 386 GERMANY PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 387 GERMANY HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 388 GERMANY GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 389 GERMANY GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 390 GERMANY IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 391 GERMANY ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 392 GERMANY OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 393 GERMANY ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 394 GERMANY PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 395 GERMANY SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 396 GERMANY H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 397 GERMANY MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 398 GERMANY ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 399 GERMANY BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 400 GERMANY BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 401 GERMANY SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 402 GERMANY INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 403 GERMANY OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 404 GERMANY INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 405 GERMANY EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 406 GERMANY REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 407 GERMANY MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 408 GERMANY GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 409 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 410 GERMANY CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 411 GERMANY SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 412 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 413 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 414 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 415 GERMANY INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 416 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 417 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 418 USD THOUSAND

TABLE 419 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 420 U.K. NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 421 U.K. PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 422 U.K. TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 423 U.K. HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 424 U.K. HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 425 U.K. ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 426 U.K. TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 427 U.K. FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 428 U.K. PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 429 U.K. MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 430 U.K. MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 431 U.K. PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 432 U.K. HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 433 U.K. GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 434 U.K. GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 435 U.K. IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 436 U.K. ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 437 U.K. OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 438 U.K. ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 439 U.K. PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 440 U.K. SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 441 U.K. H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 442 U.K. MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 443 U.K. ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 444 U.K. BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 445 U.K. BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 446 U.K. SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 447 U.K. INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 448 U.K. OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 449 U.K. INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 450 U.K. EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 451 U.K. REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 452 U.K. MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 453 U.K. GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 454 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 455 U.K. CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 456 U.K. SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 457 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 458 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 459 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 460 U.K. INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 461 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 462 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 463 USD THOUSAND

TABLE 464 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 465 FRANCE NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 466 FRANCE PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 467 FRANCE TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 468 FRANCE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 469 FRANCE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 470 FRANCE ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 471 FRANCE TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 472 FRANCE FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 473 FRANCE PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 474 FRANCE MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 475 FRANCE MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 476 FRANCE PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 477 FRANCE HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 478 FRANCE GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 479 FRANCE GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 480 FRANCE IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 481 FRANCE ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 482 FRANCE OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 483 FRANCE ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 484 FRANCE PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 485 FRANCE SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 486 FRANCE H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 487 FRANCE MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 488 FRANCE ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 489 FRANCE BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 490 FRANCE BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 491 FRANCE SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 492 FRANCE INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 493 FRANCE OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 494 FRANCE INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 495 FRANCE EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 496 FRANCE REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 497 FRANCE MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 498 FRANCE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 499 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 500 FRANCE CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 501 FRANCE SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 502 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 503 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 504 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 505 FRANCE INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 506 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 507 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 508 USD THOUSAND

TABLE 509 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 510 ITALY NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 511 ITALY PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 512 ITALY TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 513 ITALY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 514 ITALY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 515 ITALY ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 516 ITALY TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 517 ITALY FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 518 ITALY PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 519 ITALY MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 520 ITALY MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 521 ITALY PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 522 ITALY HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 523 ITALY GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 524 ITALY GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 525 ITALY IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 526 ITALY ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 527 ITALY OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 528 ITALY ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 529 ITALY PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 530 ITALY SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 531 ITALY H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 532 ITALY MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 533 ITALY ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 534 ITALY BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 535 ITALY BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 536 ITALY SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 537 ITALY INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 538 ITALY OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 539 ITALY INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 540 ITALY EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 541 ITALY REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 542 ITALY MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 543 ITALY GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 544 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 545 ITALY CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 546 ITALY SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 547 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 548 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 549 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 550 ITALY INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 551 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 552 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 553 USD THOUSAND

TABLE 554 SPAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 555 SPAIN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 556 SPAIN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 557 SPAIN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 558 SPAIN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 559 SPAIN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 560 SPAIN ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 561 SPAIN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 562 SPAIN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 563 SPAIN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 564 SPAIN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 565 SPAIN MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 566 SPAIN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 567 SPAIN HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 568 SPAIN GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 569 SPAIN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 570 SPAIN IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 571 SPAIN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 572 SPAIN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 573 SPAIN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 574 SPAIN PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 575 SPAIN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 576 SPAIN H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 577 SPAIN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 578 SPAIN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 579 SPAIN BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 580 SPAIN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 581 SPAIN SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 582 SPAIN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 583 SPAIN OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 584 SPAIN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 585 SPAIN EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 586 SPAIN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 587 SPAIN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 588 SPAIN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 589 SPAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 590 SPAIN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 591 SPAIN SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 592 SPAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 593 SPAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 594 SPAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 595 SPAIN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 596 SPAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 597 SPAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 598 USD THOUSAND

TABLE 599 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 600 TURKEY NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 601 TURKEY PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 602 TURKEY TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 603 TURKEY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 604 TURKEY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 605 TURKEY ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 606 TURKEY TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 607 TURKEY FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 608 TURKEY PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 609 TURKEY MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 610 TURKEY MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 611 TURKEY PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 612 TURKEY HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 613 TURKEY GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 614 TURKEY GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 615 TURKEY IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 616 TURKEY ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 617 TURKEY OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 618 TURKEY ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 619 TURKEY PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 620 TURKEY SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 621 TURKEY H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 622 TURKEY MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 623 TURKEY ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 624 TURKEY BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 625 TURKEY BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 626 TURKEY SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 627 TURKEY INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 628 TURKEY OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 629 TURKEY INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 630 TURKEY EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 631 TURKEY REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 632 TURKEY MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 633 TURKEY GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 634 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 635 TURKEY CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 636 TURKEY SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 637 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 638 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 639 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 640 TURKEY INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 641 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 642 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 643 USD THOUSAND

TABLE 644 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 645 RUSSIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 646 RUSSIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 647 RUSSIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 648 RUSSIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 649 RUSSIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 650 RUSSIA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 651 RUSSIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 652 RUSSIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 653 RUSSIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 654 RUSSIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 655 RUSSIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 656 RUSSIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 657 RUSSIA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 658 RUSSIA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 659 RUSSIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 660 RUSSIA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 661 RUSSIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 662 RUSSIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 663 RUSSIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 664 RUSSIA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 665 RUSSIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 666 RUSSIA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 667 RUSSIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 668 RUSSIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 669 RUSSIA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 670 RUSSIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 671 RUSSIA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 672 RUSSIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 673 RUSSIA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 674 RUSSIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 675 RUSSIA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 676 RUSSIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 677 RUSSIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 678 RUSSIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 679 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 680 RUSSIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 681 RUSSIA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 682 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 683 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 684 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 685 RUSSIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 686 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 687 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 688 USD THOUSAND

TABLE 689 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 690 NETHERLANDS NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 691 NETHERLANDS PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 692 NETHERLANDS TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 693 NETHERLANDS HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 694 NETHERLANDS HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 695 NETHERLANDS ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 696 NETHERLANDS TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 697 NETHERLANDS FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 698 NETHERLANDS PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 699 NETHERLANDS MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 700 NETHERLANDS MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 701 NETHERLANDS PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 702 NETHERLANDS HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 703 NETHERLANDS GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 704 NETHERLANDS GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 705 NETHERLANDS IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 706 NETHERLANDS ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 707 NETHERLANDS OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 708 NETHERLANDS ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 709 NETHERLANDS PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 710 NETHERLANDS SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 711 NETHERLANDS H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 712 NETHERLANDS MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 713 NETHERLANDS ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 714 NETHERLANDS BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 715 NETHERLANDS BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 716 NETHERLANDS SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 717 NETHERLANDS INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 718 NETHERLANDS OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 719 NETHERLANDS INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 720 NETHERLANDS EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 721 NETHERLANDS REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 722 NETHERLANDS MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 723 NETHERLANDS GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 724 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 725 NETHERLANDS CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 726 NETHERLANDS SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 727 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 728 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 729 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 730 NETHERLANDS INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 731 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 732 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 733 USD THOUSAND

TABLE 734 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 735 SWITZERLAND NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 736 SWITZERLAND PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 737 SWITZERLAND TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 738 SWITZERLAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 739 SWITZERLAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 740 SWITZERLAND ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 741 SWITZERLAND TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 742 SWITZERLAND FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 743 SWITZERLAND PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 744 SWITZERLAND MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 745 SWITZERLAND MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 746 SWITZERLAND PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 747 SWITZERLAND HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 748 SWITZERLAND GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 749 SWITZERLAND GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 750 SWITZERLAND IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 751 SWITZERLAND ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 752 SWITZERLAND OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 753 SWITZERLAND ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 754 SWITZERLAND PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 755 SWITZERLAND SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 756 SWITZERLAND H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 757 SWITZERLAND MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 758 SWITZERLAND ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 759 SWITZERLAND BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 760 SWITZERLAND BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 761 SWITZERLAND SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 762 SWITZERLAND INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 763 SWITZERLAND OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 764 SWITZERLAND INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 765 SWITZERLAND EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 766 SWITZERLAND REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 767 SWITZERLAND MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 768 SWITZERLAND GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 769 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 770 SWITZERLAND CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 771 SWITZERLAND SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 772 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 773 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 774 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 775 SWITZERLAND INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 776 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 777 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 778 USD THOUSAND

TABLE 779 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 780 BELGIUM NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 781 BELGIUM PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 782 BELGIUM TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 783 BELGIUM HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 784 BELGIUM HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 785 BELGIUM ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 786 BELGIUM TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 787 BELGIUM FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 788 BELGIUM PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 789 BELGIUM MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 790 BELGIUM MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 791 BELGIUM PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 792 BELGIUM HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 793 BELGIUM GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 794 BELGIUM GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 795 BELGIUM IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 796 BELGIUM ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 797 BELGIUM OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 798 BELGIUM ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 799 BELGIUM PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 800 BELGIUM SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 801 BELGIUM H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 802 BELGIUM MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 803 BELGIUM ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 804 BELGIUM BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 805 BELGIUM BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 806 BELGIUM SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 807 BELGIUM INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 808 BELGIUM OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 809 BELGIUM INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 810 BELGIUM EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 811 BELGIUM REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 812 BELGIUM MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 813 BELGIUM GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 814 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 815 BELGIUM CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 816 BELGIUM SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 817 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 818 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 819 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 820 BELGIUM INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 821 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 822 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 823 USD THOUSAND

TABLE 824 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 825 SWEDEN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 826 SWEDEN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 827 SWEDEN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 828 SWEDEN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 829 SWEDEN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 830 SWEDEN ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 831 SWEDEN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 832 SWEDEN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 833 SWEDEN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 834 SWEDEN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 835 SWEDEN MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 836 SWEDEN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 837 SWEDEN HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 838 SWEDEN GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 839 SWEDEN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 840 SWEDEN IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 841 SWEDEN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 842 SWEDEN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 843 SWEDEN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 844 SWEDEN PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 845 SWEDEN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 846 SWEDEN H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 847 SWEDEN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 848 SWEDEN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 849 SWEDEN BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 850 SWEDEN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 851 SWEDEN SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 852 SWEDEN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 853 SWEDEN OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 854 SWEDEN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 855 SWEDEN EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 856 SWEDEN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 857 SWEDEN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 858 SWEDEN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 859 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 860 SWEDEN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 861 SWEDEN SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 862 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 863 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 864 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 865 SWEDEN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 866 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 867 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 868 USD THOUSAND

TABLE 869 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 870 DENMARK NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 871 DENMARK PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 872 DENMARK TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 873 DENMARK HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 874 DENMARK HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 875 DENMARK ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 876 DENMARK TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 877 DENMARK FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 878 DENMARK PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 879 DENMARK MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 880 DENMARK MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 881 DENMARK PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 882 DENMARK HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 883 DENMARK GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 884 DENMARK GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 885 DENMARK IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 886 DENMARK ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 887 DENMARK OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 888 DENMARK ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 889 DENMARK PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 890 DENMARK SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 891 DENMARK H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 892 DENMARK MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 893 DENMARK ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 894 DENMARK BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 895 DENMARK BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 896 DENMARK SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 897 DENMARK INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 898 DENMARK OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 899 DENMARK INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 900 DENMARK EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 901 DENMARK REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 902 DENMARK MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 903 DENMARK GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 904 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 905 DENMARK CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 906 DENMARK SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 907 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 908 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 909 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 910 DENMARK INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 911 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 912 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 913 USD THOUSAND

TABLE 914 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 915 NORWAY NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 916 NORWAY PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 917 NORWAY TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 918 NORWAY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 919 NORWAY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 920 NORWAY ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 921 NORWAY TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 922 NORWAY FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 923 NORWAY PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 924 NORWAY MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 925 NORWAY MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 926 NORWAY PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 927 NORWAY HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 928 NORWAY GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 929 NORWAY GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 930 NORWAY IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 931 NORWAY ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 932 NORWAY OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 933 NORWAY ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 934 NORWAY PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 935 NORWAY SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 936 NORWAY H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 937 NORWAY MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 938 NORWAY ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 939 NORWAY BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 940 NORWAY BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 941 NORWAY SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 942 NORWAY INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 943 NORWAY OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 944 NORWAY INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 945 NORWAY EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 946 NORWAY REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 947 NORWAY MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 948 NORWAY GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 949 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 950 NORWAY CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 951 NORWAY SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 952 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 953 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 954 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 955 NORWAY INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 956 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 957 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 958 USD THOUSAND

TABLE 959 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 960 FINLAND NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 961 FINLAND PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 962 FINLAND TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 963 FINLAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 964 FINLAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 965 FINLAND ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 966 FINLAND TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 967 FINLAND FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 968 FINLAND PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 969 FINLAND MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 970 FINLAND MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 971 FINLAND PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 972 FINLAND HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 973 FINLAND GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 974 FINLAND GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 975 FINLAND IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 976 FINLAND ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 977 FINLAND OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 978 FINLAND ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 979 FINLAND PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 980 FINLAND SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 981 FINLAND H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 982 FINLAND MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 983 FINLAND ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 984 FINLAND BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 985 FINLAND BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 986 FINLAND SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 987 FINLAND INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 988 FINLAND OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 989 FINLAND INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 990 FINLAND EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 991 FINLAND REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 992 FINLAND MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 993 FINLAND GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 994 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 995 FINLAND CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 996 FINLAND SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 997 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 998 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 999 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1000 FINLAND INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1001 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1002 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1003 USD THOUSAND

TABLE 1004 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1005 REST OF EUROPE NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1006 REST OF EUROPE PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1007 REST OF EUROPE TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1008 REST OF EUROPE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1009 REST OF EUROPE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1010 REST OF EUROPE ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1011 REST OF EUROPE TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1012 REST OF EUROPE FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1013 REST OF EUROPE PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1014 REST OF EUROPE MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1015 REST OF EUROPE MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1016 REST OF EUROPE PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1017 REST OF EUROPE HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1018 REST OF EUROPE GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1019 REST OF EUROPE GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1020 REST OF EUROPE IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1021 REST OF EUROPE ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1022 REST OF EUROPE OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1023 REST OF EUROPE ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1024 REST OF EUROPE PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1025 REST OF EUROPE SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1026 REST OF EUROPE H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1027 REST OF EUROPE MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1028 REST OF EUROPE ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1029 REST OF EUROPE BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1030 REST OF EUROPE BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1031 REST OF EUROPE SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1032 REST OF EUROPE INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1033 REST OF EUROPE OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1034 REST OF EUROPE INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1035 REST OF EUROPE EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1036 REST OF EUROPE REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1037 REST OF EUROPE MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1038 REST OF EUROPE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1039 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1040 REST OF EUROPE CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1041 REST OF EUROPE SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1042 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1043 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1044 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1045 REST OF EUROPE INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1046 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1047 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1048 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)

TABLE 1049 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 1050 USD THOUSAND

TABLE 1051 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1052 ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1053 ASIA-PACIFIC PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1054 ASIA-PACIFIC TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1055 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1056 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1057 ASIA-PACIFIC ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1058 ASIA-PACIFIC TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1059 ASIA-PACIFIC FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1060 ASIA-PACIFIC PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1061 ASIA-PACIFIC MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1062 ASIA-PACIFIC MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1063 ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1064 ASIA-PACIFIC HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1065 ASIA-PACIFIC GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1066 ASIA-PACIFIC GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1067 ASIA-PACIFIC IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1068 ASIA-PACIFIC ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1069 ASIA-PACIFIC OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1070 ASIA-PACIFIC ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1071 ASIA-PACIFIC PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1072 ASIA-PACIFIC SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1073 ASIA-PACIFIC H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1074 ASIA-PACIFIC MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1075 ASIA-PACIFIC ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1076 ASIA-PACIFIC BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1077 ASIA-PACIFIC BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1078 ASIA-PACIFIC SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1079 ASIA-PACIFIC INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1080 ASIA-PACIFIC OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1081 ASIA-PACIFIC INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1082 ASIA-PACIFIC EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1083 ASIA-PACIFIC REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1084 ASIA-PACIFIC MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1085 ASIA-PACIFIC GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1086 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1087 ASIA-PACIFIC CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1088 ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1089 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1090 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1091 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1092 ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1093 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1094 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1095 USD THOUSAND

TABLE 1096 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1097 JAPAN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1098 JAPAN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1099 JAPAN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1100 JAPAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1101 JAPAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1102 JAPAN ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1103 JAPAN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1104 JAPAN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1105 JAPAN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1106 JAPAN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1107 JAPAN MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1108 JAPAN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1109 JAPAN HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1110 JAPAN GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1111 JAPAN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1112 JAPAN IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1113 JAPAN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1114 JAPAN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1115 JAPAN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1116 JAPAN PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1117 JAPAN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1118 JAPAN H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1119 JAPAN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1120 JAPAN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1121 JAPAN BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1122 JAPAN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1123 JAPAN SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1124 JAPAN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1125 JAPAN OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1126 JAPAN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1127 JAPAN EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1128 JAPAN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1129 JAPAN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1130 JAPAN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1131 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1132 JAPAN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1133 JAPAN SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1134 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1135 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1136 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1137 JAPAN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1138 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1139 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1140 USD THOUSAND

TABLE 1141 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1142 CHINA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1143 CHINA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1144 CHINA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1145 CHINA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1146 CHINA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1147 CHINA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1148 CHINA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1149 CHINA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1150 CHINA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1151 CHINA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1152 CHINA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1153 CHINA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1154 CHINA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1155 CHINA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1156 CHINA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1157 CHINA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1158 CHINA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1159 CHINA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1160 CHINA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1161 CHINA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1162 CHINA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1163 CHINA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1164 CHINA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1165 CHINA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1166 CHINA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1167 CHINA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1168 CHINA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1169 CHINA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1170 CHINA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1171 CHINA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1172 CHINA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1173 CHINA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1174 CHINA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1175 CHINA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1176 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1177 CHINA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1178 CHINA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1179 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1180 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1181 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1182 CHINA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1183 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1184 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1185 USD THOUSAND

TABLE 1186 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1187 SOUTH KOREA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1188 SOUTH KOREA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1189 SOUTH KOREA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1190 SOUTH KOREA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1191 SOUTH KOREA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1192 SOUTH KOREA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1193 SOUTH KOREA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1194 SOUTH KOREA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1195 SOUTH KOREA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1196 SOUTH KOREA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1197 SOUTH KOREA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1198 SOUTH KOREA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1199 SOUTH KOREA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1200 SOUTH KOREA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1201 SOUTH KOREA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1202 SOUTH KOREA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1203 SOUTH KOREA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1204 SOUTH KOREA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1205 SOUTH KOREA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1206 SOUTH KOREA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1207 SOUTH KOREA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1208 SOUTH KOREA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1209 SOUTH KOREA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1210 SOUTH KOREA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1211 SOUTH KOREA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1212 SOUTH KOREA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1213 SOUTH KOREA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1214 SOUTH KOREA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1215 SOUTH KOREA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1216 SOUTH KOREA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1217 SOUTH KOREA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1218 SOUTH KOREA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1219 SOUTH KOREA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1220 SOUTH KOREA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1221 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1222 SOUTH KOREA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1223 SOUTH KOREA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1224 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1225 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1226 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1227 SOUTH KOREA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1228 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1229 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1230 USD THOUSAND

TABLE 1231 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1232 INDIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1233 INDIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1234 INDIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1235 INDIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1236 INDIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1237 INDIA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1238 INDIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1239 INDIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1240 INDIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1241 INDIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1242 INDIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1243 INDIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1244 INDIA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1245 INDIA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1246 INDIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1247 INDIA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1248 INDIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1249 INDIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1250 INDIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1251 INDIA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1252 INDIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1253 INDIA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1254 INDIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1255 INDIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1256 INDIA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1257 INDIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1258 INDIA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1259 INDIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1260 INDIA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1261 INDIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1262 INDIA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1263 INDIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1264 INDIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1265 INDIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1266 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1267 INDIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1268 INDIA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1269 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1270 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1271 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1272 INDIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1273 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1274 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1275 USD THOUSAND

TABLE 1276 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1277 SINGAPORE NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1278 SINGAPORE PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1279 SINGAPORE TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1280 SINGAPORE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1281 SINGAPORE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1282 SINGAPORE ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1283 SINGAPORE TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1284 SINGAPORE FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1285 SINGAPORE PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1286 SINGAPORE MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1287 SINGAPORE MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1288 SINGAPORE PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1289 SINGAPORE HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1290 SINGAPORE GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1291 SINGAPORE GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1292 SINGAPORE IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1293 SINGAPORE ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1294 SINGAPORE OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1295 SINGAPORE ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1296 SINGAPORE PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1297 SINGAPORE SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1298 SINGAPORE H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1299 SINGAPORE MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1300 SINGAPORE ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1301 SINGAPORE BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1302 SINGAPORE BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1303 SINGAPORE SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1304 SINGAPORE INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1305 SINGAPORE OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1306 SINGAPORE INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1307 SINGAPORE EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1308 SINGAPORE REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1309 SINGAPORE MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1310 SINGAPORE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1311 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1312 SINGAPORE CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1313 SINGAPORE SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1314 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1315 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1316 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1317 SINGAPORE INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1318 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1319 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1320 USD THOUSAND

TABLE 1321 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1322 THAILAND NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1323 THAILAND PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1324 THAILAND TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1325 THAILAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1326 THAILAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1327 THAILAND ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1328 THAILAND TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1329 THAILAND FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1330 THAILAND PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1331 THAILAND MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1332 THAILAND MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1333 THAILAND PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1334 THAILAND HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1335 THAILAND GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1336 THAILAND GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1337 THAILAND IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1338 THAILAND ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1339 THAILAND OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1340 THAILAND ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1341 THAILAND PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1342 THAILAND SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1343 THAILAND H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1344 THAILAND MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1345 THAILAND ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1346 THAILAND BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1347 THAILAND BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1348 THAILAND SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1349 THAILAND INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1350 THAILAND OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1351 THAILAND INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1352 THAILAND EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1353 THAILAND REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1354 THAILAND MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1355 THAILAND GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1356 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1357 THAILAND CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1358 THAILAND SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1359 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1360 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1361 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1362 THAILAND INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1363 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1364 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1365 USD THOUSAND

TABLE 1366 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1367 INDONESIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1368 INDONESIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1369 INDONESIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1370 INDONESIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1371 INDONESIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1372 INDONESIA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1373 INDONESIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1374 INDONESIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1375 INDONESIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1376 INDONESIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1377 INDONESIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1378 INDONESIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1379 INDONESIA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1380 INDONESIA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1381 INDONESIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1382 INDONESIA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1383 INDONESIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1384 INDONESIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1385 INDONESIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1386 INDONESIA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1387 INDONESIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1388 INDONESIA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1389 INDONESIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1390 INDONESIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1391 INDONESIA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1392 INDONESIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1393 INDONESIA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1394 INDONESIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1395 INDONESIA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1396 INDONESIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1397 INDONESIA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1398 INDONESIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1399 INDONESIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1400 INDONESIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1401 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1402 INDONESIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1403 INDONESIA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1404 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1405 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1406 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1407 INDONESIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1408 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1409 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1410 USD THOUSAND

TABLE 1411 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1412 MALAYSIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1413 MALAYSIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1414 MALAYSIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1415 MALAYSIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1416 MALAYSIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1417 MALAYSIA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1418 MALAYSIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1419 MALAYSIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1420 MALAYSIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1421 MALAYSIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1422 MALAYSIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1423 MALAYSIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1424 MALAYSIA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1425 MALAYSIA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1426 MALAYSIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1427 MALAYSIA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1428 MALAYSIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1429 MALAYSIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1430 MALAYSIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1431 MALAYSIA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1432 MALAYSIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1433 MALAYSIA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1434 MALAYSIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1435 MALAYSIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1436 MALAYSIA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1437 MALAYSIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1438 MALAYSIA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1439 MALAYSIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1440 MALAYSIA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1441 MALAYSIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1442 MALAYSIA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1443 MALAYSIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1444 MALAYSIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1445 MALAYSIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1446 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1447 MALAYSIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1448 MALAYSIA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1449 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1450 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1451 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1452 MALAYSIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1453 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1454 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1455 USD THOUSAND

TABLE 1456 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1457 PHILIPPINES NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1458 PHILIPPINES PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1459 PHILIPPINES TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1460 PHILIPPINES HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1461 PHILIPPINES HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1462 PHILIPPINES ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1463 PHILIPPINES TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1464 PHILIPPINES FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1465 PHILIPPINES PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1466 PHILIPPINES MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1467 PHILIPPINES MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1468 PHILIPPINES PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1469 PHILIPPINES HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1470 PHILIPPINES GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1471 PHILIPPINES GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1472 PHILIPPINES IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1473 PHILIPPINES ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1474 PHILIPPINES OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1475 PHILIPPINES ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1476 PHILIPPINES PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1477 PHILIPPINES SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1478 PHILIPPINES H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1479 PHILIPPINES MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1480 PHILIPPINES ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1481 PHILIPPINES BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1482 PHILIPPINES BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1483 PHILIPPINES SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1484 PHILIPPINES INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1485 PHILIPPINES OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1486 PHILIPPINES INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1487 PHILIPPINES EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1488 PHILIPPINES REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1489 PHILIPPINES MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1490 PHILIPPINES GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1491 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1492 PHILIPPINES CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1493 PHILIPPINES SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1494 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1495 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1496 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1497 PHILIPPINES INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1498 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1499 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1500 USD THOUSAND

TABLE 1501 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1502 BELGIUM NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1503 BELGIUM PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1504 BELGIUM TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1505 BELGIUM HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1506 BELGIUM HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1507 BELGIUM ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1508 BELGIUM TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1509 BELGIUM FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1510 BELGIUM PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1511 BELGIUM MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1512 BELGIUM MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1513 BELGIUM PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1514 BELGIUM HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1515 BELGIUM GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1516 BELGIUM GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1517 BELGIUM IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1518 BELGIUM ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1519 BELGIUM OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1520 BELGIUM ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1521 BELGIUM PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1522 BELGIUM SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1523 BELGIUM H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1524 BELGIUM MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1525 BELGIUM ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1526 BELGIUM BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1527 BELGIUM BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1528 BELGIUM SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1529 BELGIUM INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1530 BELGIUM OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1531 BELGIUM INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1532 BELGIUM EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1533 BELGIUM REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1534 BELGIUM MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1535 BELGIUM GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1536 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1537 BELGIUM CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1538 BELGIUM SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1539 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1540 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1541 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1542 BELGIUM INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1543 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1544 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1545 USD THOUSAND

TABLE 1546 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1547 NEW ZEALAND NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1548 NEW ZEALAND PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1549 NEW ZEALAND TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1550 NEW ZEALAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1551 NEW ZEALAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1552 NEW ZEALAND ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1553 NEW ZEALAND TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1554 NEW ZEALAND FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1555 NEW ZEALAND PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1556 NEW ZEALAND MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1557 NEW ZEALAND MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1558 NEW ZEALAND PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1559 NEW ZEALAND HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1560 NEW ZEALAND GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1561 NEW ZEALAND GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1562 NEW ZEALAND IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1563 NEW ZEALAND ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1564 NEW ZEALAND OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1565 NEW ZEALAND ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1566 NEW ZEALAND PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1567 NEW ZEALAND SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1568 NEW ZEALAND H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1569 NEW ZEALAND MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1570 NEW ZEALAND ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1571 NEW ZEALAND BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1572 NEW ZEALAND BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1573 NEW ZEALAND SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1574 NEW ZEALAND INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1575 NEW ZEALAND OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1576 NEW ZEALAND INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1577 NEW ZEALAND EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1578 NEW ZEALAND REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1579 NEW ZEALAND MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1580 NEW ZEALAND GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1581 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1582 NEW ZEALAND CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1583 NEW ZEALAND SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1584 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1585 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1586 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1587 NEW ZEALAND INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1588 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1589 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1590 USD THOUSAND

TABLE 1591 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1592 HONG KONG NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1593 HONG KONG PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1594 HONG KONG TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1595 HONG KONG HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1596 HONG KONG HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1597 HONG KONG ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1598 HONG KONG TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1599 HONG KONG FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1600 HONG KONG PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1601 HONG KONG MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1602 HONG KONG MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1603 HONG KONG PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1604 HONG KONG HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1605 HONG KONG GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1606 HONG KONG GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1607 HONG KONG IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1608 HONG KONG ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1609 HONG KONG OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1610 HONG KONG ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1611 HONG KONG PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1612 HONG KONG SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1613 HONG KONG H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1614 HONG KONG MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1615 HONG KONG ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1616 HONG KONG BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1617 HONG KONG BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1618 HONG KONG SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1619 HONG KONG INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1620 HONG KONG OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1621 HONG KONG INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1622 HONG KONG EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1623 HONG KONG REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1624 HONG KONG MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1625 HONG KONG GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1626 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1627 HONG KONG CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1628 HONG KONG SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1629 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1630 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1631 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1632 HONG KONG INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1633 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1634 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1635 USD THOUSAND

TABLE 1636 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1637 TAIWAN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1638 TAIWAN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1639 TAIWAN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1640 TAIWAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1641 TAIWAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1642 TAIWAN ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1643 TAIWAN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1644 TAIWAN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1645 TAIWAN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1646 TAIWAN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1647 TAIWAN MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1648 TAIWAN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1649 TAIWAN HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1650 TAIWAN GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1651 TAIWAN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1652 TAIWAN IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1653 TAIWAN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1654 TAIWAN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1655 TAIWAN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1656 TAIWAN PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1657 TAIWAN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1658 TAIWAN H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1659 TAIWAN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1660 TAIWAN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1661 TAIWAN BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1662 TAIWAN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1663 TAIWAN SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1664 TAIWAN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1665 TAIWAN OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1666 TAIWAN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1667 TAIWAN EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1668 TAIWAN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1669 TAIWAN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1670 TAIWAN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1671 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1672 TAIWAN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1673 TAIWAN SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1674 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1675 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1676 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1677 TAIWAN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1678 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1679 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1680 USD THOUSAND

TABLE 1681 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1682 REST OF ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1683 REST OF ASIA-PACIFIC PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1684 REST OF ASIA-PACIFIC TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1685 REST OF ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1686 REST OF ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1687 REST OF ASIA-PACIFIC ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1688 REST OF ASIA-PACIFIC TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1689 REST OF ASIA-PACIFIC FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1690 REST OF ASIA-PACIFIC PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1691 REST OF ASIA-PACIFIC MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1692 REST OF ASIA-PACIFIC MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1693 REST OF ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1694 REST OF ASIA-PACIFIC HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1695 REST OF ASIA-PACIFIC GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1696 REST OF ASIA-PACIFIC GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1697 REST OF ASIA-PACIFIC IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1698 REST OF ASIA-PACIFIC ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1699 REST OF ASIA-PACIFIC OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1700 REST OF ASIA-PACIFIC ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1701 REST OF ASIA-PACIFIC PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1702 REST OF ASIA-PACIFIC SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1703 REST OF ASIA-PACIFIC H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1704 REST OF ASIA-PACIFIC MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1705 REST OF ASIA-PACIFIC ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1706 REST OF ASIA-PACIFIC BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1707 REST OF ASIA-PACIFIC BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1708 REST OF ASIA-PACIFIC SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1709 REST OF ASIA-PACIFIC INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1710 REST OF ASIA-PACIFIC OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1711 REST OF ASIA-PACIFIC INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1712 REST OF ASIA-PACIFIC EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1713 REST OF ASIA-PACIFIC REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1714 REST OF ASIA-PACIFIC MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1715 REST OF ASIA-PACIFIC GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1716 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1717 REST OF ASIA-PACIFIC CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1718 REST OF ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1719 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1720 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1721 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1722 REST OF ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1723 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1724 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1725 SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)

TABLE 1726 SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 1727 USD THOUSAND

TABLE 1728 SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1729 SOUTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1730 SOUTH AMERICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1731 SOUTH AMERICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1732 SOUTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1733 SOUTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1734 SOUTH AMERICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1735 SOUTH AMERICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1736 SOUTH AMERICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1737 SOUTH AMERICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1738 SOUTH AMERICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1739 SOUTH AMERICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1740 SOUTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1741 SOUTH AMERICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1742 SOUTH AMERICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1743 SOUTH AMERICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1744 SOUTH AMERICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1745 SOUTH AMERICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1746 SOUTH AMERICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1747 SOUTH AMERICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1748 SOUTH AMERICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1749 SOUTH AMERICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1750 SOUTH AMERICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1751 SOUTH AMERICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1752 SOUTH AMERICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1753 SOUTH AMERICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1754 SOUTH AMERICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1755 SOUTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1756 SOUTH AMERICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1757 SOUTH AMERICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1758 SOUTH AMERICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1759 SOUTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1760 SOUTH AMERICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1761 SOUTH AMERICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1762 SOUTH AMERICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1763 SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1764 SOUTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1765 SOUTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1766 SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1767 SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1768 SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1769 SOUTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1770 SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1771 SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1772 USD THOUSAND

TABLE 1773 BRAZIL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1774 BRAZIL NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1775 BRAZIL PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1776 BRAZIL TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1777 BRAZIL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1778 BRAZIL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1779 BRAZIL ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1780 BRAZIL TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1781 BRAZIL FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1782 BRAZIL PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1783 BRAZIL MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1784 BRAZIL MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1785 BRAZIL PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1786 BRAZIL HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1787 BRAZIL GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1788 BRAZIL GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1789 BRAZIL IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1790 BRAZIL ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1791 BRAZIL OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1792 BRAZIL ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1793 BRAZIL PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1794 BRAZIL SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1795 BRAZIL H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1796 BRAZIL MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1797 BRAZIL ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1798 BRAZIL BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1799 BRAZIL BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1800 BRAZIL SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1801 BRAZIL INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1802 BRAZIL OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1803 BRAZIL INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1804 BRAZIL EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1805 BRAZIL REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1806 BRAZIL MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1807 BRAZIL GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1808 BRAZIL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1809 BRAZIL CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1810 BRAZIL SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1811 BRAZIL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1812 BRAZIL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1813 BRAZIL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1814 BRAZIL INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1815 BRAZIL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1816 BRAZIL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1817 USD THOUSAND

TABLE 1818 ARGENTINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1819 ARGENTINA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1820 ARGENTINA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1821 ARGENTINA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1822 ARGENTINA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1823 ARGENTINA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1824 ARGENTINA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1825 ARGENTINA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1826 ARGENTINA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1827 ARGENTINA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1828 ARGENTINA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1829 ARGENTINA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1830 ARGENTINA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1831 ARGENTINA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1832 ARGENTINA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1833 ARGENTINA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1834 ARGENTINA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1835 ARGENTINA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1836 ARGENTINA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1837 ARGENTINA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1838 ARGENTINA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1839 ARGENTINA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1840 ARGENTINA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1841 ARGENTINA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1842 ARGENTINA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1843 ARGENTINA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1844 ARGENTINA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1845 ARGENTINA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1846 ARGENTINA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1847 ARGENTINA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1848 ARGENTINA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1849 ARGENTINA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1850 ARGENTINA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1851 ARGENTINA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1852 ARGENTINA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1853 ARGENTINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1854 ARGENTINA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1855 ARGENTINA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1856 ARGENTINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1857 ARGENTINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1858 ARGENTINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1859 ARGENTINA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1860 ARGENTINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1861 ARGENTINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1862 USD THOUSAND

TABLE 1863 COLOMBIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1864 COLOMBIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1865 COLOMBIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1866 COLOMBIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1867 COLOMBIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1868 COLOMBIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1869 COLOMBIA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1870 COLOMBIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1871 COLOMBIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1872 COLOMBIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1873 COLOMBIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1874 COLOMBIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1875 COLOMBIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1876 COLOMBIA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1877 COLOMBIA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1878 COLOMBIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1879 COLOMBIA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1880 COLOMBIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1881 COLOMBIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1882 COLOMBIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1883 COLOMBIA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1884 COLOMBIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1885 COLOMBIA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1886 COLOMBIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1887 COLOMBIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1888 COLOMBIA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1889 COLOMBIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1890 COLOMBIA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1891 -

TABLE 1892 COLOMBIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1893 COLOMBIA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1894 COLOMBIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1895 COLOMBIA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1896 COLOMBIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1897 COLOMBIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1898 COLOMBIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1899 COLOMBIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1900 COLOMBIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1901 COLOMBIA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1902 COLOMBIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1903 COLOMBIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1904 COLOMBIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1905 COLOMBIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1906 COLOMBIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1907 COLOMBIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1908 USD THOUSAND

TABLE 1909 CHILE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1910 CHILE NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1911 CHILE PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1912 CHILE TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1913 CHILE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1914 CHILE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1915 CHILE ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1916 CHILE TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1917 CHILE FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1918 CHILE PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1919 CHILE MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1920 CHILE MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1921 CHILE PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1922 CHILE HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1923 CHILE GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1924 CHILE GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1925 CHILE IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1926 CHILE ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1927 CHILE OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1928 CHILE ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1929 CHILE PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1930 CHILE SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1931 CHILE H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1932 CHILE MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1933 CHILE ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1934 CHILE BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1935 CHILE BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1936 CHILE SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1937 CHILE INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1938 CHILE OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1939 CHILE INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1940 CHILE EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1941 CHILE REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1942 CHILE MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1943 CHILE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1944 CHILE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1945 CHILE CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1946 CHILE SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1947 CHILE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1948 CHILE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1949 CHILE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1950 CHILE INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1951 CHILE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1952 CHILE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1953 USD THOUSAND

TABLE 1954 PERU TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 1955 PERU NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1956 PERU PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1957 PERU TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1958 PERU HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1959 PERU HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 1960 PERU ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1961 PERU TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1962 PERU FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1963 PERU PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1964 PERU MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1965 PERU MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1966 PERU PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1967 PERU HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1968 PERU GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1969 PERU GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 1970 PERU IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1971 PERU ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1972 PERU OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1973 PERU ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1974 PERU PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1975 PERU SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 1976 PERU H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1977 PERU MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1978 PERU ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1979 PERU BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1980 PERU BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1981 PERU SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1982 PERU INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1983 PERU OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1984 PERU INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1985 PERU EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1986 PERU REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1987 PERU MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1988 PERU GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1989 PERU TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 1990 PERU CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1991 PERU SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1992 PERU TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 1993 PERU TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 1994 PERU TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 1995 PERU INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 1996 PERU TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 1997 PERU TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 1998 USD THOUSAND

TABLE 1999 ECUADOR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2000 ECUADOR NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2001 ECUADOR PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2002 ECUADOR TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2003 ECUADOR HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2004 ECUADOR HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2005 ECUADOR ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2006 ECUADOR TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2007 ECUADOR FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2008 ECUADOR PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2009 ECUADOR MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2010 ECUADOR MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2011 ECUADOR PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2012 ECUADOR HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2013 ECUADOR GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2014 ECUADOR GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2015 ECUADOR IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2016 ECUADOR ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2017 ECUADOR OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2018 ECUADOR ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2019 ECUADOR PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2020 ECUADOR SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2021 ECUADOR H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2022 ECUADOR MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2023 ECUADOR ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2024 ECUADOR BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2025 ECUADOR BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2026 ECUADOR SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2027 ECUADOR INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2028 CUADOR OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2029 ECUADOR INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2030 ECUADOR EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2031 ECUADOR REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2032 ECUADOR MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2033 ECUADOR GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2034 ECUADOR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2035 ECUADOR CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2036 ECUADOR SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2037 ECUADOR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2038 ECUADOR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2039 ECUADOR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2040 ECUADOR INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2041 ECUADOR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2042 ECUADOR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2043 USD THOUSAND

TABLE 2044 URUGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2045 URUGUAY NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2046 URUGUAY PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2047 URUGUAY TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2048 URUGUAY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2049 URUGUAY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2050 URUGUAY ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2051 URUGUAY TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2052 URUGUAY FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2053 URUGUAY PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2054 URUGUAY MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2055 URUGUAY MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2056 URUGUAY PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2057 URUGUAY HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2058 URUGUAY GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2059 URUGUAY GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2060 URUGUAY IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2061 URUGUAY ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2062 URUGUAY OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2063 URUGUAY ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2064 URUGUAY PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2065 URUGUAY SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2066 URUGUAY H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2067 URUGUAY MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2068 URUGUAY ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2069 URUGUAY BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2070 URUGUAY BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2071 URUGUAY SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2072 URUGUAY INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2073 URUGUAY OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2074 URUGUAY INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2075 URUGUAY EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2076 URUGUAY REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2077 URUGUAY MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2078 URUGUAY GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2079 URUGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2080 URUGUAY CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2081 URUGUAY SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2082 URUGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2083 URUGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2084 URUGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2085 URUGUAY INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2086 URUGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2087 URUGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2088 USD THOUSAND

TABLE 2089 VENEZUELA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2090 VENEZUELA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2091 VENEZUELA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2092 VENEZUELA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2093 VENEZUELA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2094 VENEZUELA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2095 VENEZUELA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2096 VENEZUELA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2097 VENEZUELA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2098 VENEZUELA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2099 VENEZUELA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2100 VENEZUELA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2101 VENEZUELA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2102 VENEZUELA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2103 VENEZUELA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2104 VENEZUELA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2105 VENEZUELA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2106 VENEZUELA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2107 VENEZUELA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2108 VENEZUELA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2109 VENEZUELA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2110 VENEZUELA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2111 VENEZUELA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2112 VENEZUELA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2113 VENEZUELA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2114 VENEZUELA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2115 VENEZUELA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2116 VENEZUELA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2117 VENEZUELA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2118 VENEZUELA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2119 VENEZUELA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2120 VENEZUELA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2121 VENEZUELA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2122 VENEZUELA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2123 VENEZUELA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2124 VENEZUELA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2125 VENEZUELA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2126 VENEZUELA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2127 VENEZUELA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2128 VENEZUELA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2129 VENEZUELA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2130 VENEZUELA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2131 VENEZUELA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2132 VENEZUELA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2133 USD THOUSAND

TABLE 2134 BOLIVIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2135 BOLIVIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2136 BOLIVIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2137 BOLIVIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2138 BOLIVIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2139 BOLIVIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2140 BOLIVIA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2141 BOLIVIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2142 BOLIVIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2143 BOLIVIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2144 BOLIVIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2145 BOLIVIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2146 BOLIVIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2147 BOLIVIA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2148 BOLIVIA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2149 BOLIVIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2150 BOLIVIA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2151 BOLIVIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2152 BOLIVIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2153 BOLIVIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2154 BOLIVIA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2155 BOLIVIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2156 BOLIVIA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2157 BOLIVIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2158 BOLIVIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2159 BOLIVIA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2160 BOLIVIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2161 BOLIVIA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2162 BOLIVIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2163 BOLIVIA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2164 BOLIVIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2165 BOLIVIA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2166 BOLIVIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2167 BOLIVIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2168 BOLIVIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2169 BOLIVIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2170 BOLIVIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2171 BOLIVIA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2172 BOLIVIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2173 BOLIVIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2174 BOLIVIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2175 BOLIVIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2176 BOLIVIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2177 BOLIVIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2178 USD THOUSAND

TABLE 2179 PARAGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2180 PARAGUAY NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2181 PARAGUAY PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2182 PARAGUAY TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2183 PARAGUAY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2184 PARAGUAY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2185 PARAGUAY ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2186 PARAGUAY TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2187 PARAGUAY FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2188 PARAGUAY PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2189 PARAGUAY MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2190 PARAGUAY MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2191 PARAGUAY PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2192 PARAGUAY HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2193 PARAGUAY GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2194 PARAGUAY GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2195 PARAGUAY IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2196 PARAGUAY ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2197 PARAGUAY OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2198 PARAGUAY ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2199 PARAGUAY PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2200 PARAGUAY SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2201 PARAGUAY H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2202 PARAGUAY MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2203 PARAGUAY ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2204 PARAGUAY BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2205 PARAGUAY BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2206 PARAGUAY SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2207 PARAGUAY INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2208 PARAGUAY OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2209 PARAGUAY INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2210 PARAGUAY EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2211 PARAGUAY REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2212 PARAGUAY MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2213 PARAGUAY GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2214 PARAGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2215 PARAGUAY CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2216 PARAGUAY SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2217 PARAGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2218 PARAGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2219 PARAGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2220 PARAGUAY INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2221 PARAGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2222 PARAGUAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2223 USD THOUSAND

TABLE 2224 REST OF SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2225 REST OF SOUTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2226 REST OF SOUTH AMERICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2227 REST OF SOUTH AMERICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2228 REST OF SOUTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2229 REST OF SOUTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2230 REST OF SOUTH AMERICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2231 REST OF SOUTH AMERICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2232 REST OF SOUTH AMERICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2233 REST OF SOUTH AMERICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2234 REST OF SOUTH AMERICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2235 REST OF SOUTH AMERICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2236 REST OF SOUTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2237 REST OF SOUTH AMERICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2238 REST OF SOUTH AMERICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2239 REST OF SOUTH AMERICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2240 REST OF SOUTH AMERICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2241 REST OF SOUTH AMERICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2242 REST OF SOUTH AMERICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2243 REST OF SOUTH AMERICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2244 REST OF SOUTH AMERICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2245 REST OF SOUTH AMERICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2246 REST OF SOUTH AMERICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2247 REST OF SOUTH AMERICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2248 REST OF SOUTH AMERICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2249 REST OF SOUTH AMERICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2250 REST OF SOUTH AMERICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2251 REST OF SOUTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2252 REST OF SOUTH AMERICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2253 REST OF SOUTH AMERICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2254 REST OF SOUTH AMERICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2255 REST OF SOUTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2256 REST OF SOUTH AMERICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2257 REST OF SOUTH AMERICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2258 REST OF SOUTH AMERICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2259 REST OF SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2260 REST OF SOUTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2261 REST OF SOUTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2262 REST OF SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2263 REST OF SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2264 REST OF SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2265 REST OF SOUTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2266 REST OF SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2267 REST OF SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2268 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)

TABLE 2269 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 2270 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2271 MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2272 MIDDLE EAST AND AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2273 MIDDLE EAST AND AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2274 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2275 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2276 MIDDLE EAST AND AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2277 MIDDLE EAST AND AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2278 MIDDLE EAST AND AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2279 MIDDLE EAST AND AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2280 MIDDLE EAST AND AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2281 MIDDLE EAST AND AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2282 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2283 MIDDLE EAST AND AFRICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2284 MIDDLE EAST AND AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2285 MIDDLE EAST AND AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2286 MIDDLE EAST AND AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2287 MIDDLE EAST AND AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2288 MIDDLE EAST AND AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2289 MIDDLE EAST AND AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2290 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2291 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2292 MIDDLE EAST AND AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2293 MIDDLE EAST AND AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2294 MIDDLE EAST AND AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2295 MIDDLE EAST AND AFRICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2296 MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2297 MIDDLE EAST AND AFRICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2298 MIDDLE EAST AND AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2299 MIDDLE EAST AND AFRICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2300 MIDDLE EAST AND AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2301 MIDDLE EAST AND AFRICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2302 MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2303 MIDDLE EAST AND AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2304 MIDDLE EAST AND AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2305 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2306 MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2307 MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2308 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2309 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2310 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2311 MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2312 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2313 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2314 USD THOUSAND

TABLE 2315 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2316 SAUDI ARABIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2317 SAUDI ARABIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2318 SAUDI ARABIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2319 SAUDI ARABIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2320 SAUDI ARABIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2321 SAUDI ARABIA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2322 SAUDI ARABIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2323 SAUDI ARABIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2324 SAUDI ARABIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2325 SAUDI ARABIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2326 SAUDI ARABIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2327 SAUDI ARABIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2328 SAUDI ARABIA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2329 SAUDI ARABIA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2330 SAUDI ARABIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2331 SAUDI ARABIA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2332 SAUDI ARABIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2333 SAUDI ARABIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2334 SAUDI ARABIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2335 SAUDI ARABIA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2336 SAUDI ARABIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2337 SAUDI ARABIA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2338 SAUDI ARABIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2339 SAUDI ARABIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2340 SAUDI ARABIA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2341 SAUDI ARABIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2342 SAUDI ARABIA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2343 SAUDI ARABIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2344 SAUDI ARABIA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2345 SAUDI ARABIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2346 SAUDI ARABIA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2347 SAUDI ARABIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2348 SAUDI ARABIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2349 SAUDI ARABIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2350 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2351 SAUDI ARABIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2352 SAUDI ARABIA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2353 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2354 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2355 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2356 SAUDI ARABIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2357 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2358 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2359 USD THOUSAND

TABLE 2360 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2361 SOUTH AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2362 SOUTH AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2363 SOUTH AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2364 SOUTH AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2365 SOUTH AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2366 SOUTH AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2367 SOUTH AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2368 SOUTH AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2369 SOUTH AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2370 SOUTH AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2371 SOUTH AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2372 SOUTH AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2373 SOUTH AFRICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2374 SOUTH AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2375 SOUTH AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2376 SOUTH AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2377 SOUTH AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2378 SOUTH AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2379 SOUTH AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2380 SOUTH AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2381 SOUTH AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2382 SOUTH AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2383 SOUTH AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2384 SOUTH AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2385 SOUTH AFRICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2386 SOUTH AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2387 SOUTH AFRICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2388 SOUTH AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2389 SOUTH AFRICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2390 SOUTH AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2391 SOUTH AFRICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2392 SOUTH AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2393 SOUTH AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2394 SOUTH AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2395 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2396 SOUTH AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2397 SOUTH AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2398 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2399 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2400 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2401 SOUTH AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2402 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2403 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2404 USD THOUSAND

TABLE 2405 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2406 EGYPT NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2407 EGYPT PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2408 EGYPT TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2409 EGYPT HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2410 EGYPT HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2411 EGYPT ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2412 EGYPT TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2413 EGYPT FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2414 EGYPT PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2415 EGYPT MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2416 EGYPT MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2417 EGYPT PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2418 EGYPT HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2419 EGYPT GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2420 EGYPT GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2421 EGYPT IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2422 EGYPT ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2423 EGYPT OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2424 EGYPT ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2425 EGYPT PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2426 EGYPT SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2427 EGYPT H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2428 EGYPT MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2429 EGYPT ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2430 EGYPT BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2431 EGYPT BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2432 EGYPT SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2433 EGYPT INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2434 EGYPT OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2435 EGYPT INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2436 EGYPT EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2437 EGYPT REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2438 EGYPT MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2439 EGYPT GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2440 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2441 EGYPT CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2442 EGYPT SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2443 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2444 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2445 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2446 EGYPT INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2447 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2448 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2449 USD THOUSAND

TABLE 2450 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2451 ISRAEL NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2452 ISRAEL PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2453 ISRAEL TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2454 ISRAEL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2455 ISRAEL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2456 ISRAEL ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2457 ISRAEL TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2458 ISRAEL FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2459 ISRAEL PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2460 ISRAEL MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2461 ISRAEL MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2462 ISRAEL PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2463 ISRAEL HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2464 ISRAEL GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2465 ISRAEL GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2466 ISRAEL IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2467 ISRAEL ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2468 ISRAEL OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2469 ISRAEL ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2470 ISRAEL PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2471 ISRAEL SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2472 ISRAEL H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2473 ISRAEL MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2474 ISRAEL ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2475 ISRAEL BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2476 ISRAEL BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2477 ISRAEL SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2478 ISRAEL INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2479 ISRAEL OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2480 ISRAEL INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2481 ISRAEL EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2482 ISRAEL REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2483 ISRAEL MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2484 ISRAEL GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2485 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2486 ISRAEL CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2487 ISRAEL SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2488 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2489 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2490 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2491 ISRAEL INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2492 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2493 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2494 USD THOUSAND

TABLE 2495 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2496 UNITED ARAB EMIRATES NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2497 UNITED ARAB EMIRATES PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2498 UNITED ARAB EMIRATES TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2499 UNITED ARAB EMIRATES HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2500 UNITED ARAB EMIRATES HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2501 UNITED ARAB EMIRATES ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2502 UNITED ARAB EMIRATES TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2503 UNITED ARAB EMIRATES FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2504 UNITED ARAB EMIRATES PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2505 UNITED ARAB EMIRATES MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2506 UNITED ARAB EMIRATES MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2507 UNITED ARAB EMIRATES PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2508 UNITED ARAB EMIRATES HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2509 UNITED ARAB EMIRATES GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2510 UNITED ARAB EMIRATES GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2511 UNITED ARAB EMIRATES IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2512 UNITED ARAB EMIRATES ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2513 UNITED ARAB EMIRATES OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2514 UNITED ARAB EMIRATES ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2515 UNITED ARAB EMIRATES PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2516 UNITED ARAB EMIRATES SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2517 UNITED ARAB EMIRATES H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2518 UNITED ARAB EMIRATES MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2519 UNITED ARAB EMIRATES ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2520 UNITED ARAB EMIRATES BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2521 UNITED ARAB EMIRATES BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2522 UNITED ARAB EMIRATES SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2523 UNITED ARAB EMIRATES INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2524 UNITED ARAB EMIRATES OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2525 UNITED ARAB EMIRATES INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2526 UNITED ARAB EMIRATES EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2527 UNITED ARAB EMIRATES REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2528 UNITED ARAB EMIRATES MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2529 UNITED ARAB EMIRATES GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2530 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2531 UNITED ARAB EMIRATES CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2532 UNITED ARAB EMIRATES SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2533 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2534 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2535 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2536 UNITED ARAB EMIRATES INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2537 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2538 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2539 USD THOUSAND

TABLE 2540 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2541 KUWAIT NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2542 KUWAIT PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2543 KUWAIT TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2544 KUWAIT HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2545 KUWAIT HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2546 KUWAIT ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2547 KUWAIT TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2548 KUWAIT FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2549 KUWAIT PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2550 KUWAIT MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2551 KUWAIT MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2552 KUWAIT PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2553 KUWAIT HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2554 KUWAIT GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2555 KUWAIT GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2556 KUWAIT IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2557 KUWAIT ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2558 KUWAIT OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2559 KUWAIT ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2560 KUWAIT PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2561 KUWAIT SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2562 KUWAIT H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2563 KUWAIT MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2564 KUWAIT ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2565 KUWAIT BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2566 KUWAIT BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2567 KUWAIT SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2568 KUWAIT INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2569 KUWAIT OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2570 KUWAIT INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2571 KUWAIT EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2572 KUWAIT REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2573 KUWAIT MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2574 KUWAIT GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2575 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2576 KUWAIT CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2577 KUWAIT SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2578 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2579 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2580 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2581 KUWAIT INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2582 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2583 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2584 USD THOUSAND

TABLE 2585 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2586 OMAN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2587 OMAN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2588 OMAN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2589 OMAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2590 OMAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2591 OMAN ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2592 OMAN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2593 OMAN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2594 OMAN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2595 OMAN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2596 OMAN MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2597 OMAN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2598 OMAN HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2599 OMAN GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2600 OMAN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2601 OMAN IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2602 OMAN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2603 OMAN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2604 OMAN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2605 OMAN PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2606 OMAN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2607 OMAN H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2608 OMAN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2609 OMAN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2610 OMAN BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2611 OMAN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2612 OMAN SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2613 OMAN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2614 OMAN OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2615 OMAN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2616 OMAN EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2617 OMAN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2618 OMAN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2619 OMAN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2620 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2621 OMAN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2622 OMAN SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2623 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2624 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2625 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2626 OMAN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2627 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2628 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2629 USD THOUSAND

TABLE 2630 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2631 QATAR NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2632 QATAR PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2633 QATAR TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2634 QATAR HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2635 QATAR HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2636 QATAR ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2637 QATAR TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2638 QATAR FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2639 QATAR PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2640 QATAR MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2641 QATAR MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2642 QATAR PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2643 QATAR HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2644 QATAR GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2645 QATAR GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2646 QATAR IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2647 QATAR ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2648 QATAR OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2649 QATAR ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2650 QATAR PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2651 QATAR SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2652 QATAR H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2653 QATAR MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2654 QATAR ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2655 QATAR BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2656 QATAR BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2657 QATAR SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2658 QATAR INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2659 QATAR OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2660 QATAR INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2661 QATAR EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2662 QATAR REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2663 QATAR MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2664 QATAR GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2665 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2666 QATAR CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2667 QATAR SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2668 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2669 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2670 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2671 QATAR INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2672 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2673 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2674 USD THOUSAND

TABLE 2675 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2676 BAHRAIN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2677 BAHRAIN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2678 BAHRAIN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2679 BAHRAIN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2680 BAHRAIN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2681 BAHRAIN ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2682 BAHRAIN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2683 BAHRAIN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2684 BAHRAIN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2685 BAHRAIN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2686 BAHRAIN MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2687 BAHRAIN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2688 BAHRAIN HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2689 BAHRAIN GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2690 BAHRAIN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2691 BAHRAIN IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2692 BAHRAIN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2693 BAHRAIN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2694 BAHRAIN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2695 BAHRAIN PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2696 BAHRAIN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2697 BAHRAIN H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2698 BAHRAIN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2699 BAHRAIN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2700 BAHRAIN BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2701 BAHRAIN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2702 BAHRAIN SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2703 BAHRAIN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2704 BAHRAIN OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2705 BAHRAIN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2706 BAHRAIN EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2707 BAHRAIN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2708 BAHRAIN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2709 BAHRAIN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2710 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2711 BAHRAIN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2712 BAHRAIN SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2713 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2714 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2715 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2716 BAHRAIN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2717 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2718 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 2719 USD THOUSAND

TABLE 2720 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 2721 REST OF MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2722 REST OF MIDDLE EAST AND AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2723 REST OF MIDDLE EAST AND AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2724 REST OF MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2725 REST OF MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 2726 REST OF MIDDLE EAST AND AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2727 REST OF MIDDLE EAST AND AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2728 REST OF MIDDLE EAST AND AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2729 REST OF MIDDLE EAST AND AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2730 REST OF MIDDLE EAST AND AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2731 REST OF MIDDLE EAST AND AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2732 REST OF MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2733 REST OF MIDDLE EAST AND AFRICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2734 REST OF MIDDLE EAST AND AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2735 REST OF MIDDLE EAST AND AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 2736 REST OF MIDDLE EAST AND AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2737 REST OF MIDDLE EAST AND AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2738 REST OF MIDDLE EAST AND AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2739 REST OF MIDDLE EAST AND AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2740 REST OF MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2741 REST OF MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 2742 REST OF MIDDLE EAST AND AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2743 REST OF MIDDLE EAST AND AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2744 REST OF MIDDLE EAST AND AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2745 REST OF MIDDLE EAST AND AFRICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2746 REST OF MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2747 REST OF MIDDLE EAST AND AFRICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2748 REST OF MIDDLE EAST AND AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2749 REST OF MIDDLE EAST AND AFRICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2750 REST OF MIDDLE EAST AND AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2751 REST OF MIDDLE EAST AND AFRICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2752 REST OF MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2753 REST OF MIDDLE EAST AND AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2754 REST OF MIDDLE EAST AND AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2755 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 2756 REST OF MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2757 REST OF MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2758 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 2759 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2760 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 2761 REST OF MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 2762 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 2763 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

List of Figure

FIGURE 1 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: MULTIVARIVATE MODELING

FIGURE 10 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: PRODUCT TYPE TIMELINE CURVE

FIGURE 11 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: APPLICATION COVERAGE GRID

FIGURE 12 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION

FIGURE 13 FOUR SEGMENTS COMPRISE THE GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY (2025)

FIGURE 14 NORTH AMERICA IS EXPECTED TO BE THE DOMINANT AND ASIA-PACIFIC IS THE FASTEST GRWOING REGION IN THE GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET IN THE FORECAST PERIOD OF 2026 TO 2033

FIGURE 15 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: EXECUTIVE SUMMARY

FIGURE 16 RISING SBS-IF PATIENT POPULATION IS EXPECTED TO DRIVE THE GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET DURING THE FORECAST PERIOD OF 2026 TO 2033.

FIGURE 17 NUTRITIONAL SUPPORT THERAPY IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET IN 2026 & 2033

FIGURE 18 STRATEGIC DECISIONS

FIGURE 19 SIA-PACIFIC THE FASTEST-GROWING REGION FOR THE GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET IN THE FORECAST PERIOD OF 2026 TO 2033

FIGURE 20 PESTEL ANALYSIS

FIGURE 21 DROC ANALYSIS

FIGURE 22 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY TREATMENT MODALITY, 2025

FIGURE 23 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY MARKET ATTRIBUTION, 2025

FIGURE 24 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY DISEASE MANAGEMENT PHASE, 2025

FIGURE 25 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY PATIENT TYPE, 2025

FIGURE 26 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025

FIGURE 27 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY END USER, 2025

FIGURE 28 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025

FIGURE 29 GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)

FIGURE 30 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)

FIGURE 31 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)

FIGURE 32 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)

FIGURE 33 SOUTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)

FIGURE 34 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)

FIGURE 35 GLOBAL GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY SHARE 2025 (%)

FIGURE 36 ASIA-PACIFIC GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY SHARE 2025 (%)

FIGURE 37 EUROPE GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY SHARE 2025 (%)

FIGURE 38 NORTH AMERICA GLOBAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY SHARE 2025 (%)

View Detailed Information

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

What is the current size of the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

The Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market was valued at USD 1.12 billion in 2025 and is projected to reach USD 1.72 billion by 2033, growing at a CAGR of 7.3% from 2026 to 2033.

What is the expected growth rate of the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

The Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is expected to grow at a CAGR of 7.3% during the forecast period of 2026 to 2033, driven by the increasing prevalence of short bowel syndrome, rising adoption of advanced nutritional and pharmacological therapies, and growing awareness of intestinal rehabilitation programs.

Which region dominates the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

North America dominated the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market, accounting for a revenue share of 41.37% in 2025. The region's leadership is supported by advanced healthcare infrastructure, strong reimbursement systems, and widespread availability of specialized intestinal rehabilitation and nutritional support services.

Which region is the fastest growing in the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

Asia-Pacific is expected to be the fastest-growing region, recording a CAGR of 8.0% from 2026 to 2033. Growth is driven by improving healthcare infrastructure, increasing awareness and diagnosis of short bowel syndrome, and expanding access to specialized nutritional and pharmacological therapies. Rising healthcare expenditure, growing patient populations, and increased investments in rare disease management across countries such as China, India, and Japan are further supporting regional market expansion.

Global Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Global Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

CAGR : 7.30 %

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size

Report Scope and Type 1 SBS-IF treatment market Segmentation

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Trends

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Dynamics

Type 1 SBS-IF treatment market Scope

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Regional Analysis

Type 1 SBS-IF treatment market Share

Latest Developments in Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

What is the current size of the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

What is the expected growth rate of the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

Which region dominates the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

Which region is the fastest growing in the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

Industry Related Reports

Global Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Global Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

CAGR : 7.30 %

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size

Report Scope and Type 1 SBS-IF treatment market Segmentation

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Trends

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Dynamics

Type 1 SBS-IF treatment market Scope

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Regional Analysis

Type 1 SBS-IF treatment market Share

Latest Developments in Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

What is the current size of the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

What is the expected growth rate of the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

Which region dominates the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

Which region is the fastest growing in the Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market?

Industry Related Reports

Browse Related Pages